<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34153344</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7528</ISSN><JournalIssue CitedMedium="Internet"><Volume>127</Volume><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neuroscience and biobehavioral reviews</Title><ISOAbbreviation>Neurosci Biobehav Rev</ISOAbbreviation></Journal><ArticleTitle>Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.</ArticleTitle><Pagination><StartPage>958</StartPage><EndPage>978</EndPage><MedlinePgn>958-978</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neubiorev.2021.06.027</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0149-7634(21)00268-2</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a debilitating and rapidly fatal neurodegenerative disease. Despite decades of research and many new insights into disease biology over the 150 years since the disease was first described, causative pathogenic mechanisms in ALS remain poorly understood, especially in sporadic cases. Our understanding of the role of the immune system in ALS pathophysiology, however, is rapidly expanding. The aim of this manuscript is to summarize the recent advances regarding the immune system involvement in ALS, with particular attention to clinical translation. We focus on the potential pathophysiologic mechanism of the immune system in ALS, discussing local and systemic factors (blood, cerebrospinal fluid, and microbiota) that influence ALS onset and progression in animal models and people. We also explore the potential of Positron Emission Tomography to detect neuroinflammation in vivo, and discuss ongoing clinical trials of therapies targeting the immune system. With validation in human patients, new evidence in this emerging field will serve to identify novel therapeutic targets and provide realistic hope for personalized treatment strategies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and ALS Centre, University of Piemonte Orientale, Maggiore Della Carit&#xe0; Hospital, Corso Mazzini 18, Novara, 28100, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Munitic</LastName><ForeName>Ivana</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Immunology, Department of Biotechnology, University of Rijeka, R. Matejcic 2, 51000, Rijeka, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amedei</LastName><ForeName>Amedeo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Sean M. Healey &amp; AMG Center for ALS, Department of Neurology, Massachusetts General Hospital, 165 Cambridge Street, Suite 600, Boston, MA, 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>Eva L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aronica</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Amsterdam UMC, University of Amsterdam, Department of (Neuro) Pathology, Amsterdam Neuroscience, Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milanm, 20156, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Weehaeghe</LastName><ForeName>Donatienne</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine, Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niccolai</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prtenjaca</LastName><ForeName>Nikolina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Laboratory for Molecular Immunology, Department of Biotechnology, University of Rijeka, R. Matejcic 2, 51000, Rijeka, Croatia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakowski</LastName><ForeName>Stacey A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Michigan, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendotti</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, Milanm, 20156, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and ALS Centre, University of Piemonte Orientale, Maggiore Della Carit&#xe0; Hospital, Corso Mazzini 18, Novara, 28100, Italy. Electronic address: letizia.mazzini@uniupo.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 ES030049</GrantID><Acronym>ES</Acronym><Agency>NIEHS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 TS000289</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurosci Biobehav Rev</MedlineTA><NlmUniqueID>7806090</NlmUniqueID><ISSNLinking>0149-7634</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Immunity</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Target</Keyword><Keyword MajorTopicYN="N">Targeted therapies</Keyword></KeywordList><CoiStatement>DECLARATIONS. <b>Conflicts of interest:</b> FDM, IM, AA, JDB, ELF, EA, GN, DVW, EN, NP, SAS, CB and LM declare no disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>21</Day><Hour>20</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34153344</ArticleId><ArticleId IdType="mid">NIHMS1736973</ArticleId><ArticleId IdType="pmc">PMC8428677</ArticleId><ArticleId IdType="doi">10.1016/j.neubiorev.2021.06.027</ArticleId><ArticleId IdType="pii">S0149-7634(21)00268-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albrecht DS, Normandin MD, Shcherbinin S, Wooten DW, Schwarz AJ, Z&#xfc;rcher NR, Barth VN, Guehl NJ, Akeju O, Atassi N, 2018. Pseudoreference regions for glial imaging with 11C-PBR28: investigation in 2 clinical cohorts. J. Nucl. Med. 59, 107&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5750517</ArticleId><ArticleId IdType="pubmed">28818984</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexianu ME, Kozovska M, Appel SH, 2001. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 57, 1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">11591849</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho MJ, Z&#xfc;rcher NR, Loggia ML, Cernasov P, Reynolds B, Pijanowski O, Chonde DB, Izquierdo Garcia D, Mainero C, Catana C, 2018. Integrated magnetic resonance imaging and [11C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann. Neurol. 83, 1186&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105567</ArticleId><ArticleId IdType="pubmed">29740862</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Moreno J, Dom&#xed;nguez R, Aso E, Povedano M, Ferrer I, 2017. Inflammatory Gene Expression in Whole Peripheral Blood at Early Stages of Sporadic Amyotrophic Lateral Sclerosis. Front. Neurol. 8, 546. 10.3389/fneur.2017.00546</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00546</ArticleId><ArticleId IdType="pmc">PMC5645505</ArticleId><ArticleId IdType="pubmed">29081763</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Fabbrizio P, Amadio S, Napoli G, Verdile V, Morello G, Iemmolo R, Aronica E, Cavallaro S, Volont&#xe9; C, 2017. Histamine regulates the inflammatory profile of SOD1-G93A microglia and the histaminergic system is dysregulated in amyotrophic lateral sclerosis. Front. Immunol. 8, 1689.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5714870</ArticleId><ArticleId IdType="pubmed">29250069</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Beers DR, Henkel JS, 2010. T cell-microglial dialogue in Parkinson&#x2019;s disease and amyotrophic lateral sclerosis: are we listening? Trends Immunol. 31, 7&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126423</ArticleId><ArticleId IdType="pubmed">19879804</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Engelhardt JI, Garcia J, Stefani E, 1991. Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction. Proc. Natl. Acad. Sci. 88, 647&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC50869</ArticleId><ArticleId IdType="pubmed">1988960</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronica E, Baas F, Iyer A, ten Asbroek ALMA, Morello G, Cavallaro S, 2015. Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex. Neurobiol. Dis. 74, 359&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">25500340</ArticleId></ArticleIdList></Reference><Reference><Citation>Askew K, Li K, Olmos-Alonso A, Garcia-Moreno F, Liang Y, Richardson P, Tipton T, Chapman MA, Riecken K, Beccari S, 2017. Coupled proliferation and apoptosis maintain the rapid turnover of microglia in the adult brain. Cell Rep. 18, 391&#x2013;405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5263237</ArticleId><ArticleId IdType="pubmed">28076784</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasio A, Decman V, White D, Ramos M, Ikiz B, Lee H-C, Siao C-J, Brydges S, LaRosa E, Bai Y, Fury W, Burfeind P, Zamfirova R, Warshaw G, Orengo J, Oyejide A, Fralish M, Auerbach W, Poueymirou W, Freudenberg J, Gong G, Zambrowicz B, Valenzuela D, Yancopoulos G, Murphy A, Thurston G, Lai K-MV, 2016. C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice. Sci. Rep. 6, 23204. 10.1038/srep23204</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23204</ArticleId><ArticleId IdType="pmc">PMC4793236</ArticleId><ArticleId IdType="pubmed">26979938</ArticleId></ArticleIdList></Reference><Reference><Citation>Azevedo A, Torres T, 2018. Tofacitinib: a new oral therapy for psoriasis. Clin. Drug Investig. 38, 101&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">29094282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahia El Idrissi N, Bosch S, Ramaglia V, Aronica E, Baas F, Troost D, 2016. Complement activation at the motor end-plates in amyotrophic lateral sclerosis. J. Neuroinflammation 13, 72. 10.1186/s12974-016-0538-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0538-2</ArticleId><ArticleId IdType="pmc">PMC4823861</ArticleId><ArticleId IdType="pubmed">27056040</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee R, Mosley RL, Reynolds AD, Dhar A, Jackson-Lewis V, Gordon PH, Przedborski S, Gendelman HE, 2008. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One 3, e2740. 10.1371/journal.pone.0002740</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0002740</ArticleId><ArticleId IdType="pmc">PMC2481277</ArticleId><ArticleId IdType="pubmed">18648532</ArticleId></ArticleIdList></Reference><Reference><Citation>Barczewska M, Maksymowicz S, Zdoli&#x144;ska-Malinowska I, Siwek T, Grudniak M, 2020. Umbilical Cord Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis: an Original Study. Stem cell Rev. reports 16, 922&#x2013;932. 10.1007/s12015-020-10016-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-020-10016-7</ArticleId><ArticleId IdType="pmc">PMC7456414</ArticleId><ArticleId IdType="pubmed">32725316</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Serio A, Arjun A, Bilican B, Daub A, Ando DM, Tsvetkov A, Pleiss M, Li X, Peisach D, 2014. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat. Chem. Biol. 10, 677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4106236</ArticleId><ArticleId IdType="pubmed">24974230</ArticleId></ArticleIdList></Reference><Reference><Citation>Bataveljic D, Milosevic M, Radenovic L, Andjus P, 2014. Novel molecular biomarkers at the blood-brain barrier in ALS. Biomed Res. Int. 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4037612</ArticleId><ArticleId IdType="pubmed">24949481</ArticleId></ArticleIdList></Reference><Reference><Citation>Beecher G, Putko BN, Wagner AN, Siddiqi ZA, 2019. Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status. Drugs 79, 353&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pubmed">30762205</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH, 2019. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. 18, 211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, Siklos L, McKercher SR, Appel SH, 2006. Wild-type microglia extend survival in PU. 1 knockout mice with familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. 103, 16021&#x2013;16026.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1613228</ArticleId><ArticleId IdType="pubmed">17043238</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Appel SH, 2008a. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. 105, 15558&#x2013;15563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2547419</ArticleId><ArticleId IdType="pubmed">18809917</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Henkel JS, Zhao W, Wang J, Appel SH, Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, Brown RH, Carroll MC, Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W, Moore DH, Powell SZ, Appel SH, 2008b. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. Proc. Natl. Acad. Sci. 105, 64&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Appel SH, 2018. The Role of Regulatory T Lymphocytes in Amyotrophic Lateral Sclerosis. JAMA Neurol. 10.1001/jamaneurol.2018.0043</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0043</ArticleId><ArticleId IdType="pubmed">29507936</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Liao B, Kano O, Wang J, Huang A, Appel SH, Henkel JS, 2011. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain. Behav. Immun. 25, 1025&#x2013;1035.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3096756</ArticleId><ArticleId IdType="pubmed">21176785</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Zhao W, Wang J, Zhang X, Wen S, Neal D, Thonhoff JR, Alsuliman AS, Shpall EJ, Rezvani K, 2017. ALS patients&#x2019; regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity. JCI insight 2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333967</ArticleId><ArticleId IdType="pubmed">28289705</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;land L-C, Markovinovic A, Jakovac H, de Marchi F, Bilic E, Mazzini L, Kriz J, Munitic I, 2020. Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune responses. Brain Commun.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7585698</ArticleId><ArticleId IdType="pubmed">33134918</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjaminsen E, Alstadhaug KB, Gulsvik M, Baloch FK, Odeh F, 2018. Amyotrophic lateral sclerosis in Nordland county, Norway, 2000&#x2013;2015: prevalence, incidence, and clinical features. Amyotroph. Lateral Scler. Frontotemporal Degener. 19, 522&#x2013;527. 10.1080/21678421.2018.1513534</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1513534</ArticleId><ArticleId IdType="pubmed">30265157</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Cudkowicz ME, Windebank AJ, Staff NP, Owegi M, Nicholson K, McKenna-Yasek D, Levy YS, Abramov N, Kaspi H, 2019. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="pubmed">31740545</ArticleId></ArticleIdList></Reference><Reference><Citation>Best L, Ghadery C, Pavese N, Tai YF, Strafella AP, 2019. New and old TSPO PET radioligands for imaging brain microglial activation in neurodegenerative disease. Curr. Neurol. Neurosci. Rep. 19, 24.</Citation><ArticleIdList><ArticleId IdType="pubmed">30941587</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, Kleimeyer C, Moresi C, Harnik Y, Zur M, 2019. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature 572, 474&#x2013;480.</Citation><ArticleIdList><ArticleId IdType="pubmed">31330533</ArticleId></ArticleIdList></Reference><Reference><Citation>Boill&#xe9;e S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins NA, Kassiotis G, Kollias G, Cleveland DW, 2006. Onset and progression in inherited ALS determined by motor neurons and microglia. Science (80-. ). 312, 1389&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">16741123</ArticleId></ArticleIdList></Reference><Reference><Citation>Brambilla L, Guidotti G, Martorana F, Iyer AM, Aronica E, Valori CF, Rossi D, 2016. Disruption of the astrocytic TNFR1-GDNF axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis. Hum. Mol. Genet. 25, 3080&#x2013;3095.</Citation><ArticleIdList><ArticleId IdType="pubmed">27288458</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Hiergeist A, Adis C, Mayer B, Gessner A, Ludolph AC, Weishaupt JH, 2018. The fecal microbiome of ALS patients. Neurobiol. Aging 61, 132&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">29065369</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Sieverding K, Bruno C, L&#xfc;ningschr&#xf6;r P, Buck E, Mungwa S, Fischer L, Brockmann SJ, Ulmer J, Bliederh&#xe4;user C, Philibert CE, Satoh T, Akira S, Boill&#xe9;e S, Mayer B, Sendtner M, Ludolph AC, Danzer KM, Lobsiger CS, Freischmidt A, Weishaupt JH, 2019. Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. J. Exp. Med. 216, 267&#x2013;278. 10.1084/jem.20180729</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180729</ArticleId><ArticleId IdType="pmc">PMC6363427</ArticleId><ArticleId IdType="pubmed">30635357</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, Suh E, Van Deerlin VM, Wood EM, Baek Y, 2013. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 74, 20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A, 2017. Amyotrophic lateral sclerosis. N. Engl. J. Med. 377, 162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruno C, Sieverding K, Freischmidt A, Satoh T, Walther P, Mayer B, Ludolph AC, Akira S, Yilmazer-Hanke D, Danzer KM, Lobsiger CS, Brenner D, Weishaupt JH, 2020. Haploinsufficiency of TANK-binding kinase 1 prepones age-associated neuroinflammatory changes without causing motor neuron degeneration in aged mice. Brain Commun. 2, fcaa133. 10.1093/braincomms/fcaa133</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa133</ArticleId><ArticleId IdType="pmc">PMC7519725</ArticleId><ArticleId IdType="pubmed">33005894</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Suzuki N, Wang J-Y, Moccia R, Mordes DA, Stewart MH, Suzuki-Uematsu S, Ghosh S, Singh A, Merkle FT, Koszka K, Li Q-Z, Zon L, Rossi DJ, Trowbridge JJ, Notarangelo LD, Eggan K, 2016. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci. Transl. Med. 8, 347ra93. 10.1126/scitranslmed.aaf6038</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6038</ArticleId><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A, Wells MF, Limone F, Couto A, Smith KS, Keaney J, Gillet G, van Gastel N, Wang J-Y, Pietilainen O, 2020. C9orf72 suppresses systemic and neural inflammation induced by gut bacteria. Nature 1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7416879</ArticleId><ArticleId IdType="pubmed">32483373</ArticleId></ArticleIdList></Reference><Reference><Citation>Burda JE, Sofroniew MV, 2017. Seducing astrocytes to the dark side. Cell Res. 27, 726&#x2013;727.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5518868</ArticleId><ArticleId IdType="pubmed">28303889</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Siddiqui S, Gabriely G, Lanser AJ, Dake B, Murugaiyan G, Doykan CE, Wu PM, Gali RR, Iyer LK, 2012. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Invest. 122, 3063&#x2013;3087.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3428086</ArticleId><ArticleId IdType="pubmed">22863620</ArticleId></ArticleIdList></Reference><Reference><Citation>Caccamo A, Majumder S, Deng JJ, Bai Y, Thornton FB, Oddo S, 2009. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. J. Biol. Chem. 284, 27416&#x2013;27424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785671</ArticleId><ArticleId IdType="pubmed">19651785</ArticleId></ArticleIdList></Reference><Reference><Citation>Camu W, Mickunas M, Veyrune J-L, Payan C, Garlanda C, Locati M, Juntas-Morales R, Pageot N, Malaspina A, Andreasson U, 2020. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine 59, 102844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7502670</ArticleId><ArticleId IdType="pubmed">32651161</ArticleId></ArticleIdList></Reference><Reference><Citation>Casula M, Iyer AM, Spliet WGM, Anink JJ, Steentjes K, Sta M, Troost D, Aronica E, 2011. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience 179, 233&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pubmed">21303685</ArticleId></ArticleIdList></Reference><Reference><Citation>Chand KK, Lee KM, Lee JD, Qiu H, Willis EF, Lavidis NA, Hilliard MA, Noakes PG, 2018. Defects in synaptic transmission at the neuromuscular junction precede motor deficits in a TDP-43(Q331K) transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 32, 2676&#x2013;2689. 10.1096/fj.201700835R</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201700835R</ArticleId><ArticleId IdType="pubmed">29295857</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C-W, Lin M-J, Shen C-KJ, 2015. Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP. J. Neurogenet. 29, 59&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">26219309</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA, 2013. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41, 118&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, Mora G, 2020. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology 167, 107986.</Citation><ArticleIdList><ArticleId IdType="pubmed">32062193</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A, Lobsiger CS, Boill&#xe9;e S, 2019. New insights on the disease contribution of neuroinflammation in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 32, 764&#x2013;770.</Citation><ArticleIdList><ArticleId IdType="pubmed">31306211</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiot A, Za&#xef;di S, Iltis C, Ribon M, Berriat F, Schiaffino L, Jolly A, de la Grange P, Mallat M, Bohl D, Millecamps S, Seilhean D, Lobsiger CS, Boill&#xe9;e S, 2020. Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival. Nat. Neurosci. 23, 1339&#x2013;1351. 10.1038/s41593-020-00718-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00718-z</ArticleId><ArticleId IdType="pubmed">33077946</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, Brown RH, Carroll MC, 2008. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. 105, 17913&#x2013;17918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581614</ArticleId><ArticleId IdType="pubmed">18997009</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu IM, Phatnani H, Kuligowski M, Tapia JC, Carrasco MA, Zhang M, Maniatis T, Carroll MC, 2009. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 106, 20960&#x2013;20965. 10.1073/pnas.0911405106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0911405106</ArticleId><ArticleId IdType="pmc">PMC2791631</ArticleId><ArticleId IdType="pubmed">19933335</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S-R, Benraiss A, Chmielnicki E, Samdani A, Economides A, Goldman SA, 2007. Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease. J. Clin. Invest. 117, 2889&#x2013;2902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978427</ArticleId><ArticleId IdType="pubmed">17885687</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S-J, Hong Y-H, Kim S-M, Shin J-Y, Suh YJ, Sung J-J, 2020. High neutrophil-to-lymphocyte ratio predicts short survival duration in amyotrophic lateral sclerosis. Sci. Rep. 10, 428. 10.1038/s41598-019-57366-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-57366-y</ArticleId><ArticleId IdType="pmc">PMC6965090</ArticleId><ArticleId IdType="pubmed">31949271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cie&#x15b;lak M, Roszek K, Wujak M, 2019. Purinergic implication in amyotrophic lateral sclerosis&#x2014;from pathological mechanisms to therapeutic perspectives. Purinergic Signal. 15, 1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439052</ArticleId><ArticleId IdType="pubmed">30430356</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, Couthouis J, Lu Y-F, Wang Q, Krueger BJ, 2015. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science (80-. ). 347, 1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillee S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, 2003. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (80-. ). 302, 113&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">14526083</ArticleId></ArticleIdList></Reference><Reference><Citation>Coque E, Salsac C, Espinosa-Carrasco G, Varga B, Degauque N, Cadoux M, Crab&#xe9; R, Virenque A, Soulard C, Fierle JK, 2019. Cytotoxic CD8+ T lymphocytes expressing ALS-causing SOD1 mutant selectively trigger death of spinal motoneurons. Proc. Natl. Acad. Sci. 116, 2312&#x2013;2317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6369778</ArticleId><ArticleId IdType="pubmed">30674678</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, Nicolas G, Venel Y, Hommet C, Baulieu J-L, 2012. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One 7, e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Crisafulli SG, Brajkovic S, Mis MSC, Parente V, Corti S, 2018. Therapeutic strategies under development targeting inflammatory mechanisms in amyotrophic lateral sclerosis. Mol. Neurobiol. 55, 2789&#x2013;2813.</Citation><ArticleIdList><ArticleId IdType="pubmed">28455693</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, Drachman DB, Consortium NALS, 2006. Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. 60, 22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16802291</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Alexopoulos H, Spaeth PJ, 2020. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat. Rev. Neurol. 16, 601&#x2013;617. 10.1038/s41582-020-0400-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0400-0</ArticleId><ArticleId IdType="pmc">PMC7528717</ArticleId><ArticleId IdType="pubmed">33005040</ArticleId></ArticleIdList></Reference><Reference><Citation>De Giorgio F, Maduro C, Fisher EMC, Acevedo-Arozena A, 2019. Transgenic and physiological mouse models give insights into different aspects of amyotrophic lateral sclerosis. Dis. Model. Mech. 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6361152</ArticleId><ArticleId IdType="pubmed">30626575</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paola M, Sestito SE, Mariani A, Memo C, Fanelli R, Freschi M, Bendotti C, Calabrese V, Peri F, 2016. Synthetic and natural small molecule TLR4 antagonists inhibit motoneuron death in cultures from ALS mouse model. Pharmacol. Res. 103, 180&#x2013;187. 10.1016/j.phrs.2015.11.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2015.11.020</ArticleId><ArticleId IdType="pubmed">26640075</ArticleId></ArticleIdList></Reference><Reference><Citation>Dermentzaki G, Politi KA, Lu L, Mishra V, P&#xe9;rez-Torres EJ, Sosunov AA, McKhann GM 2nd, Lotti F, Shneider NA, Przedborski S, 2019. Deletion of Ripk3 Prevents Motor Neuron Death In Vitro but not In Vivo. eNeuro 6. 10.1523/ENEURO.0308-18.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/ENEURO.0308-18.2018</ArticleId><ArticleId IdType="pmc">PMC6391588</ArticleId><ArticleId IdType="pubmed">30815534</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Gioia D, Cionci NB, Baffoni L, Amoruso A, Pane M, Mogna L, Gagg&#xec;a F, Lucenti MA, Bersano E, Cantello R, 2020. A prospective longitudinal study on the microbiota composition in amyotrophic lateral sclerosis. BMC Med. 18, 1&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7298784</ArticleId><ArticleId IdType="pubmed">32546239</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O, Montal V, Sirisi S, L&#xf3;pez-Pernas G, Cervera-Carles L, Querol-Vilaseca M, Mu&#xf1;oz L, Belbin O, Alcolea D, Molina-Porcel L, 2020. Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurol. Neuroinflammation 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371375</ArticleId><ArticleId IdType="pubmed">32669313</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnenfeld H, Kascsak RJ, Bartfeld H, 1984. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J. Neuroimmunol. 6, 51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">6368581</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupont A-C, Largeau B, Guilloteau D, Santiago Ribeiro MJ, Arlicot N, 2018. The place of PET to assess new therapeutic effectiveness in neurodegenerative diseases. Contrast Media Mol. Imaging 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5985069</ArticleId><ArticleId IdType="pubmed">29887768</ArticleId></ArticleIdList></Reference><Reference><Citation>Duque T, Gromicho M, Pronto-Laborinho AC, de Carvalho M, 2020. Transforming growth factor-&#x3b2; plasma levels and its role in amyotrophic lateral sclerosis. Med. Hypotheses 139, 109632. 10.1016/j.mehy.2020.109632</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109632</ArticleId><ArticleId IdType="pubmed">32085981</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhart J, Smith AJ, Kuzmin-Nichols N, Zesiewicz TA, Jahan I, Shytle RD, Kim S-H, Sanberg CD, Vu TH, Gooch CL, Sanberg PR, Garbuzova-Davis S, 2015. Humoral factors in ALS patients during disease progression. J. Neuroinflammation 12, 127. 10.1186/s12974-015-0350-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0350-4</ArticleId><ArticleId IdType="pmc">PMC4487852</ArticleId><ArticleId IdType="pubmed">26126965</ArticleId></ArticleIdList></Reference><Reference><Citation>Elmore MRP, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow B, Nguyen H, West BL, 2014. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 82, 380&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161285</ArticleId><ArticleId IdType="pubmed">24742461</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo F, Komine O, Fujimori-Tonou N, Katsuno M, Jin S, Watanabe S, Sobue G, Dezawa M, Wyss-Coray T, Yamanaka K, 2015. Astrocyte-derived TGF-&#x3b2;1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. Cell Rep. 11, 592&#x2013;604. 10.1016/j.celrep.2015.03.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2015.03.053</ArticleId><ArticleId IdType="pubmed">25892237</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Appel SH, 1990. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch. Neurol. 47, 1210&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">2122877</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH, 1993. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch. Neurol. 50, 30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans MC, Couch Y, Sibson N, Turner MR, 2013. Inflammation and neurovascular changes in amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 53, 34&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">23110760</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Wang Xin, Yang S, Meng F, Wang Xiaolei, Wei H, Chen T, 2016. Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing. Front. Microbiol. 7, 1479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5028383</ArticleId><ArticleId IdType="pubmed">27703453</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman EL, Boulis NM, Hur J, Johe K, Rutkove SB, Federici T, Polak M, Bordeau J, Sakowski SA, Glass JD, 2014. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann. Neurol. 75, 363&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4005820</ArticleId><ArticleId IdType="pubmed">24510776</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Higginbottom A, Heath PR, Barber S, Greenald D, Kirby J, Shaw PJ, 2011. Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain 134, 2627&#x2013;2641. 10.1093/brain/awr193</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr193</ArticleId><ArticleId IdType="pmc">PMC3170534</ArticleId><ArticleId IdType="pubmed">21908873</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa-Romero C, Guo K, Murdock BJ, Paez-Colasante X, Bassis CM, Mikhail KA, Raue KD, Evans MC, Taubman GF, McDermott AJ, 2020. Temporal evolution of the microbiome, immune system and epigenome with disease progression in ALS mice. Dis. Model. Mech. 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6906635</ArticleId><ArticleId IdType="pubmed">31597644</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipi T, Hermanova Z, Tureckova J, Vanatko O, 2020. Glial Cells&#x2014;The Strategic Targets in Amyotrophic Lateral Sclerosis Treatment. J. Clin. Med. 9, 261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7020059</ArticleId><ArticleId IdType="pubmed">31963681</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelstein A, Kunis G, Seksenyan A, Ronen A, Berkutzki T, Azoulay D, Koronyo-Hamaoui M, Schwartz M, 2011. Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS. PLoS One 6, e22374.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3149057</ArticleId><ArticleId IdType="pubmed">21829620</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD, 2004. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185, 232&#x2013;240. 10.1016/j.expneurol.2003.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Forcina L, Cosentino M, Musar&#xf2; A, 2020. Mechanisms Regulating Muscle Regeneration: Insights into the Interrelated and Time-Dependent Phases of Tissue Healing. Cells 9. 10.3390/cells9051297</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051297</ArticleId><ArticleId IdType="pmc">PMC7290814</ArticleId><ArticleId IdType="pubmed">32456017</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, Brown RH, Salameh JS, Tansey MG, Beers DR, 2018. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 19, 242&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">29308669</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A, 2018. Inflammaging: a new immune&#x2013;metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14, 576&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">30046148</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, Ruf W, Schaeffer V, M&#xfc;ller K, Marroquin N, Nordin F, H&#xfc;bers A, Weydt P, 2015. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 18, 631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita M, Kobayashi M, Ikawa M, Gunn RN, Rabiner EA, Owen DR, Zoghbi SS, Haskali MB, Telu S, Pike VW, 2017. Comparison of four 11 C-labeled PET ligands to quantify translocator protein 18 kDa (TSPO) in human brain:(R)-PK11195, PBR28, DPA-713, and ER176&#x2014;Based on recent publications that measured specific-to-non-displaceable ratios. EJNMMI Res. 7, 1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5643834</ArticleId><ArticleId IdType="pubmed">29038960</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa T, Matsui N, Fujita K, Nodera H, Shimizu F, Miyamoto K, Takahashi Y, Kanda T, Kusunoki S, Izumi Y, Kaji R, 2015. CSF cytokine profile distinguishes multifocal motor neuropathy from progressive muscular atrophy. Neurol. Neuroimmunol. neuroinflammation 2, e138. 10.1212/NXI.0000000000000138</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000138</ArticleId><ArticleId IdType="pmc">PMC4529282</ArticleId><ArticleId IdType="pubmed">26280014</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi D, Meneri M, Saccomanno D, Bresolin N, Comi G. Pietro, Corti S, 2019. Diagnostic and Prognostic Role of Blood and Cerebrospinal Fluid and Blood Neurofilaments in Amyotrophic Lateral Sclerosis: A Review of the Literature. Int. J. Mol. Sci. 20. 10.3390/ijms20174152</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20174152</ArticleId><ArticleId IdType="pmc">PMC6747516</ArticleId><ArticleId IdType="pubmed">31450699</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandelman M, Peluffo H, Beckman JS, Cassina P, Barbeito L, 2010. Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. J. Neuroinflammation 7, 33. 10.1186/1742-2094-7-33</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-7-33</ArticleId><ArticleId IdType="pmc">PMC2901222</ArticleId><ArticleId IdType="pubmed">20534165</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Boccio KJ, Ehrhart J, Sanberg PR, Appel SH, Borlongan CV, 2021. Detection of endothelial cell-associated human DNA reveals transplanted human bone marrow stem cell engraftment into CNS capillaries of ALS mice. Brain Res. Bull. 170, 22&#x2013;28. 10.1016/j.brainresbull.2021.01.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2021.01.020</ArticleId><ArticleId IdType="pmc">PMC7990719</ArticleId><ArticleId IdType="pubmed">33545308</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Borlongan CV, 2021. Stem cell-derived extracellular vesicles as potential mechanism for repair of microvascular damage within and outside of the central nervous system in amyotrophic lateral sclerosis: perspective schema. Neural Regen. Res. 16, 680&#x2013;681. 10.4103/1673-5374.294337</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.294337</ArticleId><ArticleId IdType="pmc">PMC8067951</ArticleId><ArticleId IdType="pubmed">33063723</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Haller E, Saporta S, Kolomey I, Nicosia SV, Sanberg PR, 2007. Ultrastructure of blood&#x2013;brain barrier and blood&#x2013;spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 1157, 126&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Kurien C, Haller E, Eve DJ, Navarro S, Steiner G, Mahendrasah A, Hailu S, Khatib M, Boccio KJ, 2019. Human bone marrow endothelial progenitor cell transplantation into symptomatic ALS mice delays disease progression and increases motor neuron survival by repairing blood-spinal cord barrier. Sci. Rep. 9, 1&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437219</ArticleId><ArticleId IdType="pubmed">30918315</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Shell R, Mustafa H, Hailu S, Willing AE, Sanberg PR, Borlongan CV, 2020a. Advancing Stem Cell Therapy for Repair of Damaged Lung Microvasculature in Amyotrophic Lateral Sclerosis. Cell Transplant. 29, 963689720913494. 10.1177/0963689720913494</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0963689720913494</ArticleId><ArticleId IdType="pmc">PMC7444221</ArticleId><ArticleId IdType="pubmed">32207340</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Willing AE, Ehrhart J, Wang L, Sanberg PR, Borlongan CV, 2020b. Cell-Free Extracellular Vesicles Derived from Human Bone Marrow Endothelial Progenitor Cells as Potential Therapeutics for Microvascular Endothelium Restoration in ALS. Neuromolecular Med. 22, 503&#x2013;516. 10.1007/s12017-020-08607-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-020-08607-1</ArticleId><ArticleId IdType="pmc">PMC7677172</ArticleId><ArticleId IdType="pubmed">32820422</ArticleId></ArticleIdList></Reference><Reference><Citation>Garofalo S, Cocozza G, Porzia A, Inghilleri M, Raspa M, Scavizzi F, Aronica E, Bernardini G, Peng L, Ransohoff RM, 2020. Natural killer cells modulate motor neuron-immune cell cross talk in models of Amyotrophic Lateral Sclerosis. Nat. Commun. 11, 1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156729</ArticleId><ArticleId IdType="pubmed">32286313</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerbino V, Kaunga E, Ye J, Canzio D, O&#x2019;Keeffe S, Rudnick ND, Guarnieri P, Lutz CM, Maniatis T, 2020. The Loss of TBK1 Kinase Activity in Motor Neurons or in All Cell Types Differentially Impacts ALS Disease Progression in SOD1 Mice. Neuron 106, 789&#x2013;805.e5. 10.1016/j.neuron.2020.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.03.005</ArticleId><ArticleId IdType="pubmed">32220666</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Dedeene L, Goossens J, Claeys KG, Van Den Bosch L, Tournoy J, Van Damme P, Poesen K, 2019. Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J. Neurol. Neurosurg. Psychiatry 90, 1338&#x2013;1346. 10.1136/jnnp-2018-319586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, Stanley ER, 2010. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science (80-. ). 330, 841&#x2013;845.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3719181</ArticleId><ArticleId IdType="pubmed">20966214</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, 2017. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N. Engl. J. Med. 377, 1525&#x2013;1536.</Citation><ArticleIdList><ArticleId IdType="pubmed">29045207</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, Hertzberg VS, Boulis NM, Riley J, Federici T, Polak M, Bordeau J, Fournier C, Johe K, Hazel T, 2016. Transplantation of spinal cord&#x2013;derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology 87, 392&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977116</ArticleId><ArticleId IdType="pubmed">27358335</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldmann T, Wieghofer P, Jord&#xe3;o MJC, Prutek F, Hagemeyer N, Frenzel K, Amann L, Staszewski O, Kierdorf K, Krueger M, 2016. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol. 17, 797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968048</ArticleId><ArticleId IdType="pubmed">27135602</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, 2007. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6, 1045&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">17980667</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorter RP, Stephenson J, Nutma E, Anink J, de Jonge JC, Baron W, Jahrei&#x3b2; M, Belien JAM, van Noort JM, Mijnsbergen C, 2019. Rapidly progressive amyotrophic lateral sclerosis is associated with microglial reactivity and small heat shock protein expression in reactive astrocytes. Neuropathol. Appl. Neurobiol. 45, 459&#x2013;475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7379307</ArticleId><ArticleId IdType="pubmed">30346063</ArticleId></ArticleIdList></Reference><Reference><Citation>Gothelf Y, Abramov N, Harel A, Offen D, 2014. Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells. Clin. Transl. Med. 3, 21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4108239</ArticleId><ArticleId IdType="pubmed">25097724</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, 2017. Diagnosis and clinical management of amyotrophic lateral sclerosis and other motor neuron disorders. Contin. Lifelong Learn. Neurol. 23, 1332&#x2013;1359.</Citation><ArticleIdList><ArticleId IdType="pubmed">28968365</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Brown MB, Glass JD, Boulis NM, Johe K, Hazel T, Cudkowicz M, Atassi N, Borges L, Patil PG, 2018. Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann. Clin. Transl. Neurol. 5, 730&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5989736</ArticleId><ArticleId IdType="pubmed">29928656</ArticleId></ArticleIdList></Reference><Reference><Citation>Granucci EJ, Griciuc A, Mueller KA, Mills AN, Le H, Dios AM, McGinty D, Pereira J, Elmaleh D, Berry JD, Paganoni S, Cudkowicz ME, Tanzi RE, Sadri-Vakili G, 2019. Cromolyn sodium delays disease onset and is neuroprotective in the SOD1(G93A) Mouse Model of amyotrophic lateral sclerosis. Sci. Rep. 9, 17728. 10.1038/s41598-019-53982-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-53982-w</ArticleId><ArticleId IdType="pmc">PMC6881366</ArticleId><ArticleId IdType="pubmed">31776380</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravel M, B&#xe9;land L-C, Soucy G, Abdelhamid E, Rahimian R, Gravel C, Kriz J, 2016. IL-10 controls early microglial phenotypes and disease onset in ALS caused by misfolded superoxide dismutase 1. J. Neurosci. 36, 1031&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6601999</ArticleId><ArticleId IdType="pubmed">26791230</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves M, Fiala M, Dinglasan LA, Liu N, Sayre J, Chiappelli F, van Kooten C, Vinters H, 2004. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 5, 213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">15799549</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, McDade K, Livesey MR, Croy I, Marion de Proce S, Aitman T, Chandran S, Smith C, 2020. Spatial transcriptomics identifies spatially dysregulated expression of GRM3 and USP47 in amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol.</Citation><ArticleIdList><ArticleId IdType="pubmed">31925813</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilarte TR, 2019. TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward. Pharmacol. Ther. 194, 44&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348013</ArticleId><ArticleId IdType="pubmed">30189290</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo J, Yang X, Gao L, Zang D, 2017. Evaluating the levels of CSF and serum factors in ALS. Brain Behav. 7, e00637. 10.1002/brb3.637</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.637</ArticleId><ArticleId IdType="pmc">PMC5346523</ArticleId><ArticleId IdType="pubmed">28293476</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta K, Harvima IT, 2018. Mast cell-neural interactions contribute to pain and itch. Immunol. Rev. 282, 168&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5812374</ArticleId><ArticleId IdType="pubmed">29431216</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng HX, 1994. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772&#x2013;1775. 10.1126/science.8209258</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Gustafson MP, Staff NP, Bornschlegl S, Butler GW, Maas ML, Kazamel M, Zubair A, Gastineau DA, Windebank AJ, Dietz AB, 2017. Comprehensive immune profiling reveals substantial immune system alterations in a subset of patients with amyotrophic lateral sclerosis. PLoS One 12, e0182002. 10.1371/journal.pone.0182002</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0182002</ArticleId><ArticleId IdType="pmc">PMC5526569</ArticleId><ArticleId IdType="pubmed">28742871</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib N, Avraham-Davidi I, Basu A, Burks T, Shekhar K, Hofree M, Choudhury SR, Aguet F, Gelfand E, Ardlie K, 2017. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat. Methods 14, 955&#x2013;958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5623139</ArticleId><ArticleId IdType="pubmed">28846088</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, Van Den Berg LH, 2017. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 3, 17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison JM, Rafuse VF, 2020. Muscle fiber-type specific terminal Schwann cell pathology leads to sprouting deficits following partial denervation in SOD1G93A mice. Neurobiol. Dis. 145, 105052.</Citation><ArticleIdList><ArticleId IdType="pubmed">32827689</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LR, Rothstein JD, 2016. C9ORF72-ALS/FTD: Transgenic Mice Make a Come-BAC. Neuron 90, 427&#x2013;431. 10.1016/j.neuron.2016.04.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.026</ArticleId><ArticleId IdType="pmc">PMC7045171</ArticleId><ArticleId IdType="pubmed">27151634</ArticleId></ArticleIdList></Reference><Reference><Citation>He L, Pei H, Lan T, Tang M, Zhang C, Chen L, 2017. Design and synthesis of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis. Arch. Pharm. (Weinheim). 350, 1700194.</Citation><ArticleIdList><ArticleId IdType="pubmed">28944566</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Sikl&#xf3;s L, Appel SH, 2006. The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol. Cell. Neurosci. 31, 427&#x2013;437.</Citation><ArticleIdList><ArticleId IdType="pubmed">16337133</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W, Moore DH, Powell SZ, Appel SH, 2013. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 5, 64&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3569654</ArticleId><ArticleId IdType="pubmed">23143995</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JI, Sikl&#xf3;s L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR, Appel SH, 2004. Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann. Neurol. Off. J. Am. Neurol. Assoc. Child Neurol. Soc. 55, 221&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JIJI, Sikl&#xf3;s L, Simpson EP, Kim SH, Pan T, Goodman JC, Siddique T, Beers DR, Appel SH, Casula M, Iyer AM, Spliet WGM, Anink JJ, Steentjes K, Sta M, Troost D, Aronica E, Brambilla L, Guidotti G, Martorana F, Iyer AM, Aronica E, Valori CF, Rossi D, Tortarolo M, Lo Coco D, Veglianese P, Vallarola A, Giordana MT, Marcon G, Beghi E, Poloni M, Strong MJ, Iyer AM, Gorter RP, Stephenson J, Nutma E, Anink JJ, de Jonge JC, Baron W, Jahrei&#x3b2; M, Belien JAM, van Noort JM, Mijnsbergen C, Sofroniew MV, Pehar M, Harlan BA, Killoy KM, Vargas MR, Johann S, Filipi T, Hermanova Z, Tureckova J, Vanatko O, Lee J, Hyeon SJ, Im H, Ryu HH, Kim Y, Ryu HH, Sta M, Sylva-Steenland RMR, Casula M, de Jong JMBV, Troost D, Aronica E, Baas F, Garofalo S, Cocozza G, Porzia A, Inghilleri M, Raspa M, Scavizzi F, Aronica E, Bernardini G, Peng L, Ransohoff RM, Smitt PAES, Blaauwgeers HGT, Troost D, de Jong JMBV, Lyon MS, Wosiski-Kuhn M, Gillespie R, Caress J, Milligan C, Engelhardt JIJI, Tajti J, Appel SH, McGeer PL, McGeer EG, Kawamata T, Akiyama H, Yamada T, McGeer PL, Troost D, Van den Oord JJ, JONG JMBVDE, Schiffer D, Cordera S, Cavalla P, Migheli A, 2017. Inflammation, Immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Neuropathol. Appl. Neurobiol. 23, 401&#x2013;410.</Citation></Reference><Reference><Citation>Heurich B, El Idrissi NB, Donev RM, Petri S, Claus P, Neal J, Morgan BP, Ramaglia V, 2011. Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. J. Neuroimmunol. 235, 104&#x2013;109. 10.1016/j.jneuroim.2011.03.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2011.03.011</ArticleId><ArticleId IdType="pubmed">21501881</ArticleId></ArticleIdList></Reference><Reference><Citation>Holm&#xf8;y T, 2008. T cells in amyotrophic lateral sclerosis. Eur. J. Neurol. 15, 360&#x2013;366. 10.1111/j.1468-1331.2008.02065.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2008.02065.x</ArticleId><ArticleId IdType="pubmed">18266871</ArticleId></ArticleIdList></Reference><Reference><Citation>Houi K, Kobayashi T, Kato S, Mochio S, Inoue K, 2002. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. Acta Neurol. Scand. 106, 299&#x2013;301. 10.1034/j.1600-0404.2002.01301.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2002.01301.x</ArticleId><ArticleId IdType="pubmed">12371924</ArticleId></ArticleIdList></Reference><Reference><Citation>Howard JF, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, 2020. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 77, 582&#x2013;592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042797</ArticleId><ArticleId IdType="pubmed">32065623</ArticleId></ArticleIdList></Reference><Reference><Citation>I&#x142;zecka J, Stelmasiak Z, Dobosz B, 2002. Transforming growth factor-Beta 1 (tgf-Beta 1) in patients with amyotrophic lateral sclerosis. Cytokine 20, 239&#x2013;243. 10.1006/cyto.2002.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.2002.2005</ArticleId><ArticleId IdType="pubmed">12550109</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha MK, Jo M, Kim J-H, Suk K, 2019. Microglia-astrocyte crosstalk: an intimate molecular conversation. Neurosci. 25, 227&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">29931997</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, Stauffer JE, Jafar-Nejad P, Drenner K, Schulte D, Chun S, Sun S, Ling S-C, Myers B, Engelhardt J, Katz M, Baughn M, Platoshyn O, Marsala M, Watt A, Heyser CJ, Ard MC, De Muynck L, Daughrity LM, Swing DA, Tessarollo L, Jung CJ, Delpoux A, Utzschneider DT, Hedrick SM, de Jong PJ, Edbauer D, Van Damme P, Petrucelli L, Shaw CE, Bennett CF, Da Cruz S, Ravits J, Rigo F, Cleveland DW, Lagier-Tourenne C, 2016. Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. Neuron 90, 535&#x2013;550. 10.1016/j.neuron.2016.04.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M, G&#xfc;nther R, Akg&#xfc;n K, Hermann A, Ziemssen T, 2020. Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. Sci. Rep. 10, 5941. 10.1038/s41598-020-62756-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-62756-8</ArticleId><ArticleId IdType="pmc">PMC7125229</ArticleId><ArticleId IdType="pubmed">32246039</ArticleId></ArticleIdList></Reference><Reference><Citation>Johann S, 2017. Astrocytes pathology in ALS: A potential therapeutic target? Curr. Pharm. Des. 23, 5022&#x2013;5036.</Citation><ArticleIdList><ArticleId IdType="pubmed">28619000</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansson A, Engler H, Blomquist G, Scott B, Wall A, Aquilonius S-M, L&#xe5;ngstr&#xf6;m B, Askmark H, 2007. Evidence for astrocytosis in ALS demonstrated by [11C](L)-deprenyl-D2 PET. J. Neurol. Sci. 255, 17&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17346749</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones MK, Nair A, Gupta M, 2019. Mast Cells in Neurodegenerative Disease. Front. Cell. Neurosci. 13, 171. 10.3389/fncel.2019.00171</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00171</ArticleId><ArticleId IdType="pmc">PMC6524694</ArticleId><ArticleId IdType="pubmed">31133804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucaite A, Svenningsson P, Rinne JO, Cselenyi Z, Varn&#xe4;s K, Johnstr&#xf6;m P, Amini N, Kirjavainen A, Helin S, Minkwitz M, 2015. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson&#x2019;s disease. Brain 138, 2687&#x2013;2700.</Citation><ArticleIdList><ArticleId IdType="pubmed">26137956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kano O, Beers DR, Henkel JS, Appel SH, 2012. Peripheral nerve inflammation in ALS mice: cause or consequence. Neurology 78, 833&#x2013;835. 10.1212/WNL.0b013e318249f776</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318249f776</ArticleId><ArticleId IdType="pmc">PMC3304948</ArticleId><ArticleId IdType="pubmed">22377817</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Banno H, Suzuki K, Tanaka F, Sobue G, 2011. Transforming growth factor-&#x3b2; signaling in motor neuron diseases. Curr. Mol. Med. 11, 48&#x2013;56. 10.2174/156652411794474356</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156652411794474356</ArticleId><ArticleId IdType="pubmed">21189118</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawamata T, Akiyama H, Yamada T, McGeer PL, 1992. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140, 691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1886170</ArticleId><ArticleId IdType="pubmed">1347673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettenmann H, Hanisch U-K, Noda M, Verkhratsky A, 2011. Physiology of microglia. Physiol. Rev. 91, 461&#x2013;553.</Citation><ArticleIdList><ArticleId IdType="pubmed">21527731</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid SI, Ampie L, Kelly R, Ladha SS, Dardis C, 2017. Immune modulation in the treatment of amyotrophic lateral sclerosis: a review of clinical trials. Front. Neurol. 8, 486.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5622209</ArticleId><ArticleId IdType="pubmed">28993751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H, Kim HY, Choi MR, Hwang S, Nam K-H, Kim H-C, Han JS, Kim KS, Yoon HS, Kim SH, 2010. Dose-dependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. Neurosci. Lett. 468, 190&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">19879334</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HY, Kim H, Oh K, Oh S, Koh S, Baik W, Noh MY, Kim KS, Kim SH, 2014. Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study. Stem Cells 32, 2724&#x2013;2731.</Citation><ArticleIdList><ArticleId IdType="pubmed">24966156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kipnis J, Gadani S, Derecki NC, 2012. Pro-cognitive properties of T cells. Nat. Rev. Immunol. 12, 663&#x2013;669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4032225</ArticleId><ArticleId IdType="pubmed">22903149</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M, Aebischer P, Svendsen CN, 2005. GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum. Gene Ther. 16, 509&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">15871682</ArticleId></ArticleIdList></Reference><Reference><Citation>Krokidis MG, Vlamos P, 2018. Transcriptomics in amyotrophic lateral sclerosis. Front Biosci (Elite Ed) 10, 103&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">28930607</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, Tanaka Y, 2014. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann. Rheum. Dis. 73, 2192&#x2013;2198.</Citation><ArticleIdList><ArticleId IdType="pubmed">24013646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Lindberg RLP, Regeniter A, Mehling M, Steck AJ, Kappos L, Czaplinski A, 2009. Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur. J. Neurol. 16, 771&#x2013;774. 10.1111/j.1468-1331.2009.02560.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2009.02560.x</ArticleId><ArticleId IdType="pubmed">19236470</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon M, Noh M, Oh K, Cho K, Kang B, Kim K, Kim Y, Kim SH, 2014. The immunomodulatory effects of human mesenchymal stem cells on peripheral blood mononuclear cells in ALS patients. J. Neurochem. 131, 206&#x2013;218.</Citation><ArticleIdList><ArticleId IdType="pubmed">24995608</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai JD, Ichida JK, 2019. C9ORF72 protein function and immune dysregulation in amyotrophic lateral sclerosis. Neurosci. Lett. 713, 134523.</Citation><ArticleIdList><ArticleId IdType="pubmed">31568865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Hyeon SJ, Im H, Ryu Hyun, Kim Y, Ryu Hoon, 2016. Astrocytes and microglia as non-cell autonomous players in the pathogenesis of ALS. Exp. Neurobiol. 25, 233&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5081469</ArticleId><ArticleId IdType="pubmed">27790057</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Kamaruzaman NA, Fung JNT, Taylor SM, Turner BJ, Atkin JD, Woodruff TM, Noakes PG, 2013. Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J. Neuroinflammation 10, 119. 10.1186/1742-2094-10-119</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-10-119</ArticleId><ArticleId IdType="pmc">PMC3850877</ArticleId><ArticleId IdType="pubmed">24067070</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Kumar V, Fung JNT, Ruitenberg MJ, Noakes PG, Woodruff TM, 2017. Pharmacological inhibition of complement C5a-C5a(1) receptor signalling ameliorates disease pathology in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. Br. J. Pharmacol. 174, 689&#x2013;699. 10.1111/bph.13730</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13730</ArticleId><ArticleId IdType="pmc">PMC5368046</ArticleId><ArticleId IdType="pubmed">28128456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Levin SC, Willis EF, Li R, Woodruff TM, Noakes PG, 2018. Complement components are upregulated and correlate with disease progression in the TDP-43(Q331K) mouse model of amyotrophic lateral sclerosis. J. Neuroinflammation 15, 171. 10.1186/s12974-018-1217-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1217-2</ArticleId><ArticleId IdType="pmc">PMC5984816</ArticleId><ArticleId IdType="pubmed">29859100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JW, Sicre de Fontbrune F, Wong Lee Lee L, Pessoa V, Gualandro S, F&#xfc;reder W, Ptushkin V, Rottinghaus ST, Volles L, Shafner L, 2019. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 133, 530&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367644</ArticleId><ArticleId IdType="pubmed">30510080</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Lee JD, Phipps S, Noakes PG, Woodruff TM, 2015. Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1 G93A mouse model of amyotrophic lateral sclerosis. J. Neuroinflammation 12, 90. 10.1186/s12974-015-0310-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0310-z</ArticleId><ArticleId IdType="pmc">PMC4431460</ArticleId><ArticleId IdType="pubmed">25962427</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore AC, O&#x2019;Donnell J, Kim AS, Williams T, Tuteja A, Rao MS, Kelley LL, Campanelli JT, Maragakis NJ, 2011. Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1G93A mouse model of ALS. PLoS One 6, e25968.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3187829</ArticleId><ArticleId IdType="pubmed">21998733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore AC, Rauck B, Dejea C, Pardo AC, Rao MS, Rothstein JD, Maragakis NJ, 2008. Focal transplantation&#x2013;based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat. Neurosci. 11, 1294&#x2013;1301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656686</ArticleId><ArticleId IdType="pubmed">18931666</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Barres BA, 2017. Reactive astrocytes: production, function, and therapeutic potential. Immunity 46, 957&#x2013;967.</Citation><ArticleIdList><ArticleId IdType="pubmed">28636962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind A-L, Wu D, Freyhult E, Bodolea C, Ekegren T, Larsson A, Gustafsson MG, Katila L, Bergquist J, Gordh T, Landegren U, Kamali-Moghaddam M, 2016. A Multiplex Protein Panel Applied to Cerebrospinal Fluid Reveals Three New Biomarker Candidates in ALS but None in Neuropathic Pain Patients. PLoS One 11, e0149821. 10.1371/journal.pone.0149821</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0149821</ArticleId><ArticleId IdType="pmc">PMC4767403</ArticleId><ArticleId IdType="pubmed">26914813</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Gao L, Zang D, 2015. Elevated Levels of IFN-&#x3b3; in CSF and Serum of Patients with Amyotrophic Lateral Sclerosis. PLoS One 10, e0136937. 10.1371/journal.pone.0136937</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0136937</ArticleId><ArticleId IdType="pmc">PMC4557946</ArticleId><ArticleId IdType="pubmed">26332465</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR, Yachnis AT, Ranum LPW, 2016. C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. Neuron 90, 521&#x2013;534. 10.1016/j.neuron.2016.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.005</ArticleId><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Coco D, Veglianese P, Allievi E, Bendotti C, 2007. Distribution and cellular localization of high mobility group box protein 1 (HMGB1) in the spinal cord of a transgenic mouse model of ALS. Neurosci. Lett. 412, 73&#x2013;77. 10.1016/j.neulet.2006.10.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2006.10.063</ArticleId><ArticleId IdType="pubmed">17196331</ArticleId></ArticleIdList></Reference><Reference><Citation>Longinetti E, Fang F, 2019. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr. Opin. Neurol. 32, 771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-H, Allen K, Oei F, Leoni E, Kuhle J, Tree T, Fratta P, Sharma N, Sidle K, Howard R, Orrell R, Fish M, Greensmith L, Pearce N, Gallo V, Malaspina A, 2016. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. neuroinflammation 3, e244. 10.1212/NXI.0000000000000244</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Luchena C, Zuazo-Ibarra J, Alberdi E, Matute C, Capetillo-Zarate E, 2018. Contribution of Neurons and Glial Cells to Complement-Mediated Synapse Removal during Development, Aging and in Alzheimer&#x2019;s Disease. Mediators Inflamm. 2018, 2530414. 10.1155/2018/2530414</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/2530414</ArticleId><ArticleId IdType="pmc">PMC6252206</ArticleId><ArticleId IdType="pubmed">30533998</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyon MS, Wosiski-Kuhn M, Gillespie R, Caress J, Milligan C, 2019. Inflammation, Immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle Nerve 59, 10&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">29979464</ArticleId></ArticleIdList></Reference><Reference><Citation>Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishii K, 2012. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-&#x3b3; and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 64, 1790&#x2013;1798.</Citation><ArticleIdList><ArticleId IdType="pubmed">22147632</ArticleId></ArticleIdList></Reference><Reference><Citation>Malaspina A, Puentes F, Amor S, 2015. Disease origin and progression in amyotrophic lateral sclerosis: an immunology perspective. Int. Immunol. 27, 117&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">25344935</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Amedei A, Cammarota G, Niccolai E, Zucchi E, Ricci F, Quaranta G, Spanu T, Masucci L, 2019. FETR-ALS study protocol: a randomized clinical trial of fecal microbiota transplantation in amyotrophic lateral sclerosis. Front. Neurol. 10, 1021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6763586</ArticleId><ArticleId IdType="pubmed">31620079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, D&#x2019;Amico R, Zucchi E, Gessani A, Fini N, Fasano A, Caponnetto C, Chi&#xf2; A, Bella ED, Lunetta C, Mazzini L, Marinou K, Sorar&#xf9; G, De Biasi S, Lo Tartaro D, Pinti M, Nichelli P, Vicini R, Cabona C, Calvo A, Moglia C, Manera U, Fuda G, Canosa A, Ilardi A, Lauria G, Dalla Bella E, Gerardi F, Scognamiglio A, De Marchi F, Mora G, Gizzi M, Cossarizza A, 2018. Rapamycin treatment for amyotrophic lateral sclerosis protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial). Med. (United States) 97. 10.1097/MD.0000000000011119</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011119</ArticleId><ArticleId IdType="pmc">PMC6024184</ArticleId><ArticleId IdType="pubmed">29901635</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniatis S, &#xc4;ij&#xf6; T, Vickovic S, Braine C, Kang K, Mollbrink A, Fagegaltier D, Andrusivov&#xe1; &#x17d;, Saarenp&#xe4;&#xe4; S, Saiz-Castro G, 2019. Spatiotemporal dynamics of molecular pathology in amyotrophic lateral sclerosis. Science (80-. ). 364, 89&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">30948552</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S, Garbelli S, Pasini A, Alimonti D, Perotti C, Melazzini M, Bendotti C, Mora G, 2009. Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. J. Neuroimmunol. 210, 73&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">19307024</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini C, Cistaro A, Campi C, Calvo A, Caponnetto C, Nobili FM, Fania P, Beltrametti MC, Moglia C, Novi G, 2016. A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis. Eur. J. Nucl. Med. Mol. Imaging 43, 2061&#x2013;2071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007279</ArticleId><ArticleId IdType="pubmed">27421971</ArticleId></ArticleIdList></Reference><Reference><Citation>Marini C, Morbelli S, Cistaro A, Campi C, Caponnetto C, Bauckneht M, Bellini A, Buschiazzo A, Calamia I, Beltrametti MC, 2018. Interplay between spinal cord and cerebral cortex metabolism in amyotrophic lateral sclerosis. Brain 141, 2272&#x2013;2279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6061793</ArticleId><ArticleId IdType="pubmed">30730551</ArticleId></ArticleIdList></Reference><Reference><Citation>Markovinovic A, Ljutic T, B&#xe9;land L-C, Munitic I, 2018. Optineurin Insufficiency Disbalances Proinflammatory and Anti-inflammatory Factors by Reducing Microglial IFN-&#x3b2; Responses. Neuroscience 388, 139&#x2013;151. 10.1016/j.neuroscience.2018.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2018.07.007</ArticleId><ArticleId IdType="pubmed">30017954</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Merino L, Iridoy M, Galbete A, Rold&#xe1;n M, Rivero A, Acha B, Ir&#xfa;n P, Canosa C, Pocov&#xed; M, Mendioroz M, Jeric&#xf3; I, 2018. Evaluation of Chitotriosidase and CC-Chemokine Ligand 18 as Biomarkers of Microglia Activation in Amyotrophic Lateral Sclerosis. Neurodegener. Dis. 18, 208&#x2013;215. 10.1159/000490920</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000490920</ArticleId><ArticleId IdType="pubmed">30134252</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, 2010. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuch A, Shieh C, van Rooijen N, van Calker D, Biber K, 2016. Mechanism of microglia neuroprotection: involvement of P2X 7, TNF &#x3b1;, and valproic acid. Glia 64, 76&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">26295445</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda T, Itoh J, Koide T, Tomidokoro Y, Takei Y, Ishii K, Tamaoka A, 2017. Transforming growth factor-&#x3b2;1 in the cerebrospinal fluid of patients with distinct neurodegenerative diseases. J. Clin. Neurosci. Off. J. Neurosurg. Soc. Australas. 35, 47&#x2013;49. 10.1016/j.jocn.2016.09.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2016.09.018</ArticleId><ArticleId IdType="pubmed">27756506</ArticleId></ArticleIdList></Reference><Reference><Citation>May C, Nordhoff E, Casjens S, Turewicz M, Eisenacher M, Gold R, Br&#xfc;ning T, Pesch B, Stephan C, Woitalla D, 2014. Highly immunoreactive IgG antibodies directed against a set of twenty human proteins in the sera of patients with amyotrophic lateral sclerosis identified by protein array. PLoS One 9, e89596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3935926</ArticleId><ArticleId IdType="pubmed">24586901</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH, 2019. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 137, 715&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, O&#x2019;Rourke JG, Y&#xe1;&#xf1;ez A, Markman JL, Ho R, Wang X, Chen S, Lall D, Jin M, Muhammad AKMG, Bell S, Landeros J, Valencia V, Harms M, Arditi M, Jefferies C, Baloh RH, 2020. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature 585, 96&#x2013;101. 10.1038/s41586-020-2625-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2625-x</ArticleId><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>McGill RB, Steyn FJ, Ngo ST, Thorpe KA, Heggie S, Ruitenberg MJ, Henderson RD, McCombe PA, Woodruff TM, 2020. Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. Brain Commun. 2, fcaa013. 10.1093/braincomms/fcaa013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcaa013</ArticleId><ArticleId IdType="pmc">PMC7530830</ArticleId><ArticleId IdType="pubmed">33033799</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, Asselain B, Guillet P, Leigh PN, Ludolph A, Lacomblez L, Robberecht W, 2006. Pentoxifylline in ALS: a double-blind, randomized, multicenter, placebo-controlled trial. Neurology 66, 88&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">16401852</ArticleId></ArticleIdList></Reference><Reference><Citation>Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V, 2009. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph. Lateral Scler. 10, 378&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pubmed">19922128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA, 2019. ALS genetics, mechanisms, and therapeutics: Where are we now? Front. Neurosci. 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Milo&#x161;evi&#x107; M, Mili&#x107;evi&#x107; K, Bo&#x17e;i&#x107; I, Lavrnja I, Stevanovi&#x107; I, Bijeli&#x107; D, Dubai&#x107; M, &#x17d;ivkovi&#x107; I, Stevi&#x107; Z, Giniatullin R, 2017. Immunoglobulins G from sera of amyotrophic lateral sclerosis patients induce oxidative stress and upregulation of antioxidative system in BV-2 microglial cell line. Front. Immunol. 8, 1619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5703705</ArticleId><ArticleId IdType="pubmed">29218049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra P-S, Dhull DK, Nalini A, Vijayalakshmi K, Sathyaprabha TN, Alladi PA, Raju TR, 2016. Astroglia acquires a toxic neuroinflammatory role in response to the cerebrospinal fluid from amyotrophic lateral sclerosis patients. J. Neuroinflammation 13, 212. 10.1186/s12974-016-0698-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0698-0</ArticleId><ArticleId IdType="pmc">PMC5006495</ArticleId><ArticleId IdType="pubmed">27578023</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, Connor JR, 2009. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 72, 14&#x2013;19. 10.1212/01.wnl.0000333251.36681.a5</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000333251.36681.a5</ArticleId><ArticleId IdType="pubmed">18987350</ArticleId></ArticleIdList></Reference><Reference><Citation>Monif M, Burnstock G, Williams DA, 2010. Microglia: proliferation and activation driven by the P2X7 receptor. Int. J. Biochem. Cell Biol. 42, 1753&#x2013;1756.</Citation><ArticleIdList><ArticleId IdType="pubmed">20599520</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hern&#xe1;ndez M, Mar&#xed;n S, Mascias J, Rodriguez GE, Povedano M, 2020. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph. Lateral Scler. Front. Degener. 21, 5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Mordes DA, Morrison BM, Ament XH, Cantrell C, Mok J, Eggan P, Xue C, Wang J-Y, Eggan K, Rothstein JD, 2020. Absence of Survival and Motor Deficits in 500 Repeat C9ORF72 BAC Mice. Neuron 108, 775&#x2013;783.e4. 10.1016/j.neuron.2020.08.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.009</ArticleId><ArticleId IdType="pubmed">33022228</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Dest&#xe9;e A, Tonnel AB, Lassalle P, Just N, 2005. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology 65, 1958&#x2013;1960. 10.1212/01.wnl.0000188907.97339.76</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000188907.97339.76</ArticleId><ArticleId IdType="pubmed">16380619</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G, Spampinato AG, Cavallaro S, 2017. Neuroinflammation and ALS: transcriptomic insights into molecular disease mechanisms and therapeutic targets. Mediators Inflamm. 2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610842</ArticleId><ArticleId IdType="pubmed">29081603</ArticleId></ArticleIdList></Reference><Reference><Citation>Munitic I, Giardino Torchia ML, Meena NP, Zhu G, Li CC, Ashwell JD, 2013. Optineurin insufficiency impairs IRF3 but not NF-&#x3ba;B activation in immune cells. J. Immunol. 191, 6231&#x2013;6240. 10.4049/jimmunol.1301696</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1301696</ArticleId><ArticleId IdType="pmc">PMC3886234</ArticleId><ArticleId IdType="pubmed">24244017</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Bender DE, Kashlan SR, Figueroa-Romero C, Backus C, Callaghan BC, Goutman SA, Feldman EL, 2016. Increased ratio of circulating neutrophils to monocytes in amyotrophic lateral sclerosis. Neurol. Neuroinflammation 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4897983</ArticleId><ArticleId IdType="pubmed">27308304</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Bender DE, Segal BM, Feldman EL, 2015. The dual roles of immunity in ALS: injury overrides protection. Neurobiol. Dis. 77, 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">25726748</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdock BJ, Zhou T, Kashlan SR, Little RJ, Goutman SA, Feldman EL, 2017. Correlation of peripheral immunity with rapid amyotrophic lateral sclerosis progression. JAMA Neurol. 74, 1446&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822195</ArticleId><ArticleId IdType="pubmed">28973548</ArticleId></ArticleIdList></Reference><Reference><Citation>Naor S, Keren Z, Bronshtein T, Goren E, Machluf M, Melamed D, 2009. Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. J. Neurol. 256, 1228&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pubmed">19280101</ArticleId></ArticleIdList></Reference><Reference><Citation>Narayanaswami V, Dahl K, Bernard-Gauthier V, Josephson L, Cumming P, Vasdev N, 2018. Emerging PET radiotracers and targets for imaging of neuroinflammation in neurodegenerative diseases: outlook beyond TSPO. Mol. Imaging 17, 1536012118792317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6134492</ArticleId><ArticleId IdType="pubmed">30203712</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, de Vito G, Cecchi R, Riva N, Dina G, Heath PR, Quattrini A, Shaw PJ, Piazza V, Bendotti C, 2016. Immune response in peripheral axons delays disease progression in SOD1(G93A) mice. J. Neuroinflammation 13, 261. 10.1186/s12974-016-0732-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0732-2</ArticleId><ArticleId IdType="pmc">PMC5055725</ArticleId><ArticleId IdType="pubmed">27717377</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, Verderio M, Mariani A, de Paola M, Riva N, Dina G, Panini N, Erba E, Quattrini A, Bendotti C, 2018. Counteracting roles of MHCI and CD8(+) T cells in the peripheral and central nervous system of ALS SOD1(G93A) mice. Mol. Neurodegener. 13, 42. 10.1186/s13024-018-0271-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0271-7</ArticleId><ArticleId IdType="pmc">PMC6085701</ArticleId><ArticleId IdType="pubmed">30092791</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson LM, Topol B, Kaye W, Williamson D, Horton DK, Mehta P, Wagner T, 2018. Estimation of the prevalence of amyotrophic lateral sclerosis in the United States using national administrative healthcare data from 2002 to 2004 and capture-recapture methodology. Neuroepidemiology 51, 149&#x2013;157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250049</ArticleId><ArticleId IdType="pubmed">30092573</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K, Bjornevik K, Abu-Ali G, Chan J, Cortese M, Dedi B, Jeon M, Xavier R, Huttenhower C, Ascherio A, 2020. The human gut microbiota in people with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Front. Degener. 1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33135936</ArticleId></ArticleIdList></Reference><Reference><Citation>Nimmerjahn A, Kirchhoff F, Helmchen F, 2005. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science (80-. ). 308, 1314&#x2013;1318.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831717</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Muhammad AKMG, Gendron TF, Kim KJ, Austin A, Cady J, Liu EY, Zarrow J, Grant S, Ho R, Bell S, Carmona S, Simpkinson M, Lall D, Wu K, Daughrity L, Dickson DW, Harms MB, Petrucelli L, Lee EB, Lutz CM, Baloh RH, 2015. C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. Neuron 88, 892&#x2013;901. 10.1016/j.neuron.2015.10.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.10.027</ArticleId><ArticleId IdType="pmc">PMC4672384</ArticleId><ArticleId IdType="pubmed">26637796</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke JG, Bogdanik L, Y&#xe1;&#xf1;ez A, Lall D, Wolf AJ, Muhammad AKMG, Ho R, Carmona S, Vit JP, Zarrow J, Kim KJ, Bell S, Harms MB, Miller TM, Dangler CA, Underhill DM, Goodridge HS, Lutz CM, Baloh RH, 2016. C9orf72 is required for proper macrophage and microglial function in mice. Science 351, 1324&#x2013;1329. 10.1126/science.aaf1064</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1064</ArticleId><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ob&#xe1;l I, Klausz G, M&#xe1;ndi Y, Deli M, Sikl&#xf3;s L, Engelhardt JI, 2016. Intraperitoneally administered IgG from patients with amyotrophic lateral sclerosis or from an immune-mediated goat model increase the levels of TNF-&#x3b1;, IL-6, and IL-10 in the spinal cord and serum of mice. J. Neuroinflammation 13, 1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879728</ArticleId><ArticleId IdType="pubmed">27220674</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh K-W, Moon C, Kim HY, Oh S, Park J, Lee JH, Chang IY, Kim KS, Kim SH, 2015. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis. Stem Cells Transl. Med. 4, 590&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4449093</ArticleId><ArticleId IdType="pubmed">25934946</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh K, Noh M, Kwon M, Kim HY, Oh S, Park J, Kim H, Ki C, Kim SH, 2018. Repeated intrathecal mesenchymal stem cells for amyotrophic lateral sclerosis. Ann. Neurol. 84, 361&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6175096</ArticleId><ArticleId IdType="pubmed">30048006</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr MT, Lanier LL, 2010. Natural killer cell education and tolerance. Cell 142, 847&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945212</ArticleId><ArticleId IdType="pubmed">20850008</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani MR, Gonzalez LE, Uchitel OD, 2011. Autoimmunity in amyotrophic lateral sclerosis: past and present. Neurol. Res. Int. 2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3150148</ArticleId><ArticleId IdType="pubmed">21826267</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Alshikho MJ, Luppino S, Chan J, Pothier L, Schoenfeld D, Andres PL, Babu S, Z&#xfc;rcher NR, Loggia ML, Barry RL, Luotti S, Nardo G, Trolese MC, Pantalone S, Bendotti C, Bonetto V, De Marchi F, Rosen B, Hooker J, Cudkowicz M, Atassi N, 2019. A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle and Nerve 59. 10.1002/mus.26385</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26385</ArticleId><ArticleId IdType="pmc">PMC6379136</ArticleId><ArticleId IdType="pubmed">30458059</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma E, Reyes-Ruiz JM, Lopergolo D, Roseti C, Bertollini C, Ruffolo G, Cifelli P, Onesti E, Limatola C, Miledi R, Inghilleri M, 2016. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc. Natl. Acad. Sci. U. S. A. 113, 3060&#x2013;3065. 10.1073/pnas.1600251113</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1600251113</ArticleId><ArticleId IdType="pmc">PMC4801305</ArticleId><ArticleId IdType="pubmed">26929355</ArticleId></ArticleIdList></Reference><Reference><Citation>Pehar M, Harlan BA, Killoy KM, Vargas MR, 2017. Role and therapeutic potential of astrocytes in amyotrophic lateral sclerosis. Curr. Pharm. Des. 23, 5010&#x2013;5021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5740017</ArticleId><ArticleId IdType="pubmed">28641533</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Cabrera GT, Tran H, Gendron TF, McKeon JE, Metterville J, Weiss A, Wightman N, Salameh J, Kim J, Sun H, Boylan KB, Dickson D, Kennedy Z, Lin Z, Zhang Y-J, Daughrity L, Jung C, Gao F-B, Sapp PC, Horvitz HR, Bosco DA, Brown SP, de Jong P, Petrucelli L, Mueller C, Brown RHJ, 2015. Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. Neuron 88, 902&#x2013;909. 10.1016/j.neuron.2015.11.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.018</ArticleId><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters S, Zitzelsperger E, Kuespert S, Iberl S, Heydn R, Johannesen S, Petri S, Aigner L, Thal DR, Hermann A, Weishaupt JH, Bruun T-H, Bogdahn U, 2017. The TGF-&#x3b2; System As a Potential Pathogenic Player in Disease Modulation of Amyotrophic Lateral Sclerosis. Front. Neurol. 8, 669. 10.3389/fneur.2017.00669</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00669</ArticleId><ArticleId IdType="pmc">PMC5736544</ArticleId><ArticleId IdType="pubmed">29326641</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrou P, Gothelf Y, Argov Z, Gotkine M, Levy YS, Kassis I, Vaknin-Dembinsky A, Ben-Hur T, Offen D, Abramsky O, 2016. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 73, 337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V, Valdmanis PN, Gould PV, Julien J-P, Dupr&#xe9; N, 2016. From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathol. Commun. 4, 70. 10.1186/s40478-016-0340-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0340-5</ArticleId><ArticleId IdType="pmc">PMC4940869</ArticleId><ArticleId IdType="pubmed">27400686</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhakar S, Marwaha N, Lal V, Sharma RR, Rajan R, Khandelwal N, 2012. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study. Neurol. India 60, 465.</Citation><ArticleIdList><ArticleId IdType="pubmed">23135021</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullen AH, Demestre M, Howard RS, Orrell RW, 2004. Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by Ca 2+ enhancement. Acta Neuropathol. 107, 35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">14551798</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratai E-M, Alshikho MJ, Z&#xfc;rcher NR, Loggia ML, Cebulla CL, Cernasov P, Reynolds B, Fish J, Seth R, Babu S, 2018. Integrated imaging of [11C]-PBR28 PET, MR diffusion and magnetic resonance spectroscopy 1H-MRS in amyotrophic lateral sclerosis. NeuroImage Clin. 20, 357&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6092554</ArticleId><ArticleId IdType="pubmed">30112276</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits JM, La Spada AR, 2009. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73, 805&#x2013;811. 10.1212/WNL.0b013e3181b6bbbd</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181b6bbbd</ArticleId><ArticleId IdType="pmc">PMC2739608</ArticleId><ArticleId IdType="pubmed">19738176</ArticleId></ArticleIdList></Reference><Reference><Citation>Redmond DE, Bjugstad KB, Teng YD, Ourednik V, Ourednik J, Wakeman DR, Parsons XH, Gonzalez R, Blanchard BC, Kim SU, 2007. Behavioral improvement in a primate Parkinson&#x2019;s model is associated with multiple homeostatic effects of human neural stem cells. Proc. Natl. Acad. Sci. 104, 12175&#x2013;12180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1896134</ArticleId><ArticleId IdType="pubmed">17586681</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, Van Swieten JC, Myllykangas L, 2011. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts K, Zeineddine R, Corcoran L, Li W, Campbell IL, Yerbury JJ, 2013. Extracellular aggregated Cu/Zn superoxide dismutase activates microglia to give a cytotoxic phenotype. Glia 61, 409&#x2013;419. 10.1002/glia.22444</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22444</ArticleId><ArticleId IdType="pubmed">23281114</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas F, Cortes N, Abarzua S, Dyrda A, Van Zundert BAJ, 2014. Astrocytes expressing mutant SOD1 and TDP43 trigger motoneuron death that is mediated via sodium channels and nitroxidative stress. Front. Cell. Neurosci. 8, 24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916762</ArticleId><ArticleId IdType="pubmed">24570655</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O&#x2019;Regan JP, Deng H-X, 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi C, Cusimano M, Zambito M, Finardi A, Capotondo A, Garcia-Manteiga JM, Comi G, Furlan R, Martino G, Muzio L, 2018. Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis. Cell Death Dis. 9, 250. 10.1038/s41419-018-0288-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0288-4</ArticleId><ArticleId IdType="pmc">PMC5833860</ArticleId><ArticleId IdType="pubmed">29445154</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowin J, Xia Y, Jung B, Sun J, 2017. Gut inflammation and dysbiosis in human motor neuron disease. Physiol. Rep. 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5617930</ArticleId><ArticleId IdType="pubmed">28947596</ArticleId></ArticleIdList></Reference><Reference><Citation>Rusconi M, Gerardi F, Santus W, Lizio A, Sansone VA, Lunetta C, Zanoni I, Granucci F, 2017. Inflammatory role of dendritic cells in amyotrophic lateral sclerosis revealed by an analysis of patients&#x2019; peripheral blood. Sci. Rep. 7, 1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5552769</ArticleId><ArticleId IdType="pubmed">28798369</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo MV, McGavern DB, 2016. Inflammatory neuroprotection following traumatic brain injury. Science (80-. ). 353, 783&#x2013;785.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5260471</ArticleId><ArticleId IdType="pubmed">27540166</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadan O, Bahat-Stromza M, Barhum Y, Levy YS, Pisnevsky A, Peretz H, Ilan AB, Bulvik S, Shemesh N, Krepel D, 2009. Protective effects of neurotrophic factor&#x2013;secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev. 18, 1179&#x2013;1190.</Citation><ArticleIdList><ArticleId IdType="pubmed">19243240</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandborn WJ, Su C, Sands BE, D&#x2019;Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, 2017. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723&#x2013;1736.</Citation><ArticleIdList><ArticleId IdType="pubmed">28467869</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M, Piancone F, Tortorella P, Marventano I, Gatti A, Caputo D, Lunetta C, Corbo M, Rovaris M, Clerici M, 2013. T helper-17 activation dominates the immunologic milieu of both amyotrophic lateral sclerosis and progressive multiple sclerosis. Clin. Immunol. 148, 79&#x2013;88. 10.1016/j.clim.2013.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2013.04.010</ArticleId><ArticleId IdType="pubmed">23665549</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, 2011. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 70, 349&#x2013;359.</Citation><ArticleIdList><ArticleId IdType="pubmed">21487309</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R, Ransohoff RM, Greenberg ME, Barres BA, Stevens B, 2012. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3528177</ArticleId><ArticleId IdType="pubmed">22632727</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffer D, Cordera S, Cavalla P, Migheli A, 1996. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 139, 27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8899654</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber S, Schreiber F, Garz C, Debska-Vielhaber G, Assmann A, Perosa V, Petri S, Dengler R, Nestor P, Vielhaber S, 2019. Toward in vivo determination of peripheral nervous system immune activity in amyotrophic lateral sclerosis. Muscle Nerve 59, 567&#x2013;576. 10.1002/mus.26444</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26444</ArticleId><ArticleId IdType="pubmed">30734322</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz M, Shechter R, 2010. Systemic inflammatory cells fight off neurodegenerative disease. Nat. Rev. Neurol. 6, 405.</Citation><ArticleIdList><ArticleId IdType="pubmed">20531383</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebba A, 2008. Tocilizumab: the first interleukin-6-receptor inhibitor. Am. J. Heal. Pharm. 65, 1413&#x2013;1418.</Citation><ArticleIdList><ArticleId IdType="pubmed">18653811</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheean RK, McKay FC, Cretney E, Bye CR, Perera ND, Tomas D, Weston RA, Scheller KJ, Djouma E, Menon P, Schibeci SD, Marmash N, Yerbury JJ, Nutt SL, Booth DR, Stewart GJ, Kiernan MC, Vucic S, Turner BJ, 2018. Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. JAMA Neurol. 75, 681&#x2013;689. 10.1001/jamaneurol.2018.0035</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2018.0035</ArticleId><ArticleId IdType="pmc">PMC5885208</ArticleId><ArticleId IdType="pubmed">29507931</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi N, Kawano Y, Tateishi T, Kikuchi H, Osoegawa M, Ohyagi Y, Kira J, 2007. Increased IL-13-producing T cells in ALS: positive correlations with disease severity and progression rate. J. Neuroimmunol. 182, 232&#x2013;235. 10.1016/j.jneuroim.2006.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2006.10.001</ArticleId><ArticleId IdType="pubmed">17097743</ArticleId></ArticleIdList></Reference><Reference><Citation>Si Y, Kim S, Cui X, Zheng L, Oh SJ, Anderson T, AlSharabati M, Kazamel M, Volpicelli-Daley L, Bamman MM, Yu S, King PH, 2015. Transforming Growth Factor Beta (TGF-&#x3b2;) Is a Muscle Biomarker of Disease Progression in ALS and Correlates with Smad Expression. PLoS One 10, e0138425. 10.1371/journal.pone.0138425</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0138425</ArticleId><ArticleId IdType="pmc">PMC4574401</ArticleId><ArticleId IdType="pubmed">26375954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sironi F, Vallarola A, Violatto MB, Talamini L, Freschi M, De Gioia R, Capelli C, Agostini A, Moscatelli D, Tortarolo M, Bigini P, Introna M, Bendotti C, 2017. Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice. Stem Cell Res. 25, 166&#x2013;178. 10.1016/j.scr.2017.11.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2017.11.005</ArticleId><ArticleId IdType="pubmed">29154076</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper SD, Facci L, Giusti P, 2013. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol. Neurobiol. 48, 340&#x2013;352. 10.1007/s12035-013-8487-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-013-8487-6</ArticleId><ArticleId IdType="pubmed">23813098</ArticleId></ArticleIdList></Reference><Reference><Citation>Slowicka K, Vereecke L, Mc Guire C, Sze M, Maelfait J, Kolpe A, Saelens X, Beyaert R, van Loo G, 2016. Optineurin deficiency in mice is associated with increased sensitivity to Salmonella but does not affect proinflammatory NF-&#x3ba;B signaling. Eur. J. Immunol. 46, 971&#x2013;980. 10.1002/eji.201545863</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201545863</ArticleId><ArticleId IdType="pubmed">26677802</ArticleId></ArticleIdList></Reference><Reference><Citation>Smitt PAES, Blaauwgeers HGT, Troost D, de Jong JMBV, 1992. Metallothionein immunoreactivity is increased in the spinal cord of patients with amyotrophic lateral sclerosis. Neurosci. Lett. 144, 107&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">1436688</ArticleId></ArticleIdList></Reference><Reference><Citation>Sofroniew MV, 2015. Astrocyte barriers to neurotoxic inflammation. Nat. Rev. Neurosci. 16, 249&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5253239</ArticleId><ArticleId IdType="pubmed">25891508</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, Suzuki K, Saito K, Tanaka Y, 2014. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology 53, 914&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pubmed">24441153</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller KJ, Restrepo CR, Khan T, Dominique MA, Fang TC, Canter RG, Roberts CJ, Miller KR, Ransohoff RM, Trojanowski JQ, Lee VM-Y, 2018. Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy. Nat. Neurosci. 21, 329&#x2013;340. 10.1038/s41593-018-0083-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0083-7</ArticleId><ArticleId IdType="pmc">PMC5857237</ArticleId><ArticleId IdType="pubmed">29463850</ArticleId></ArticleIdList></Reference><Reference><Citation>Sta M, Sylva-Steenland RMR, Casula M, de Jong J, Troost D, Aronica E, Baas F, 2011. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol. Dis. 42, 211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pubmed">21220013</ArticleId></ArticleIdList></Reference><Reference><Citation>Staff NP, Madigan NN, Morris J, Jentoft M, Sorenson EJ, Butler G, Gastineau D, Dietz A, Windebank AJ, 2016. Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS. Neurology 87, 2230&#x2013;2234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5123559</ArticleId><ArticleId IdType="pubmed">27784774</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Hendrich C, Sperfeld AD, Jesse S, von Arnim CAF, Lehnert S, Pabst A, Uttner I, Tumani H, Lee VM-Y, Trojanowski JQ, Kretzschmar HA, Ludolph A, Neumann M, Otto M, 2008. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch. Neurol. 65, 1481&#x2013;1487. 10.1001/archneur.65.11.1481</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.11.1481</ArticleId><ArticleId IdType="pmc">PMC2690860</ArticleId><ArticleId IdType="pubmed">19001167</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva KD, Mehalow AK, Huberman AD, Stafford B, 2007. The classical complement cascade mediates CNS synapse elimination. Cell 131, 1164&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">18083105</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun H, B&#xe9;nardais K, Stanslowsky N, Thau-Habermann N, Hensel N, Huang D, Claus P, Dengler R, Stangel M, Petri S, 2013. Therapeutic potential of mesenchymal stromal cells and MSC conditioned medium in amyotrophic lateral sclerosis (ALS)-in vitro evidence from primary motor neuron cultures, NSC-34 cells, astrocytes and microglia. PLoS One 8, e72926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3771979</ArticleId><ArticleId IdType="pubmed">24069165</ArticleId></ArticleIdList></Reference><Reference><Citation>Swarup V, Phaneuf D, Bareil C, Robertson J, Rouleau GA, Kriz J, Julien J-P, 2011. Pathological hallmarks of amyotrophic lateral sclerosis/frontotemporal lobar degeneration in transgenic mice produced with TDP-43 genomic fragments. Brain 134, 2610&#x2013;2626.</Citation><ArticleIdList><ArticleId IdType="pubmed">21752789</ArticleId></ArticleIdList></Reference><Reference><Citation>Swash M, 2020. Chitinases, neuroinflammation and biomarkers in ALS. J. Neurol. Neurosurg. Psychiatry. 10.1136/jnnp-2019-322520</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322520</ArticleId><ArticleId IdType="pubmed">31937583</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadesse T, Gearing M, Senitzer D, Saxe D, Brat DJ, Bray R, Gebel H, Hill C, Boulis N, Riley J, 2014. Analysis of graft survival in a trial of stem cell transplant in ALS. Ann. Clin. Transl. Neurol. 1, 900&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4265061</ArticleId><ArticleId IdType="pubmed">25540804</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam OH, Rozhkov NV, Shaw R, Kim D, Hubbard I, Fennessey S, Propp N, Phatnani H, Kwan J, Sareen D, 2019. Postmortem cortex samples identify distinct molecular subtypes of als: retrotransposon activation, oxidative stress, and activated glia. Cell Rep. 29, 1164&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6866666</ArticleId><ArticleId IdType="pubmed">31665631</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA, 2008. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 28, 687&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2394854</ArticleId><ArticleId IdType="pubmed">18468463</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateishi T, Yamasaki R, Tanaka M, Matsushita T, Kikuchi H, Isobe N, Ohyagi Y, Kira J, 2010. CSF chemokine alterations related to the clinical course of amyotrophic lateral sclerosis. J. Neuroimmunol. 222, 76&#x2013;81. 10.1016/j.jneuroim.2010.03.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2010.03.004</ArticleId><ArticleId IdType="pubmed">20381883</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW, 2016. Decoding ALS: from genes to mechanism. Nature 539, 197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng YD, Benn SC, Kalkanis SN, Shefner JM, Onario RC, Cheng B, Lachyankar MB, Marconi M, Li J, Yu D, 2012. Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci. Transl. Med. 4, 165ra164&#x2013;165ra164.</Citation><ArticleIdList><ArticleId IdType="pubmed">23253611</ArticleId></ArticleIdList></Reference><Reference><Citation>Teng YD, Lavik EB, Qu X, Park KI, Ourednik J, Zurakowski D, Langer R, Snyder EY, 2002. Functional recovery following traumatic spinal cord injury mediated by a unique polymer scaffold seeded with neural stem cells. Proc. Natl. Acad. Sci. 99, 3024&#x2013;3029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC122466</ArticleId><ArticleId IdType="pubmed">11867737</ArticleId></ArticleIdList></Reference><Reference><Citation>Thangavelu SR, Tripathi PP, Arya U, Mishra HK, Subramaniam JR, 2011. ALS associated mutant SOD1 impairs the motor neurons and astrocytes and wild type astrocyte secreted-factors reverse the impaired motor neurons. Ann. Neurosci. 18, 48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4117032</ArticleId><ArticleId IdType="pubmed">25205921</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Bampton A, Raciborska D, Talbot K, Turner MR, 2019. CSF chitinase proteins in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 90, 1215&#x2013;1220. 10.1136/jnnp-2019-320442</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-320442</ArticleId><ArticleId IdType="pubmed">31123140</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Beers DR, Zhao W, Pleitez M, Simpson EP, Berry JD, Cudkowicz ME, Appel SH, 2018a. Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study. Neurol. Neuroinflammation 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5961523</ArticleId><ArticleId IdType="pubmed">29845093</ArticleId></ArticleIdList></Reference><Reference><Citation>Thonhoff JR, Simpson EP, Appel SH, 2018b. Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. Curr. Opin. Neurol. 31, 635&#x2013;639. 10.1097/WCO.0000000000000599</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000599</ArticleId><ArticleId IdType="pubmed">30048339</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorarensen A, Dowty ME, Banker ME, Juba B, Jussif J, Lin T, Vincent F, Czerwinski RM, Casimiro-Garcia A, Unwalla R, 2017. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2 S, 5 R)-5-((7 H-Pyrrolo [2, 3-d] pyrimidin-4-yl) amino)-2-methylpiperidin-1-yl) prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. J. Med. Chem. 60, 1971&#x2013;1993.</Citation><ArticleIdList><ArticleId IdType="pubmed">28139931</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo G, Iaccarino L, Cerami C, Vanoli GE, Presotto L, Masiello V, Coliva A, Salvi F, Bartolomei I, Mosca L, n.d.11C-PK11195 PET&#x2013;based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7480909</ArticleId><ArticleId IdType="pubmed">32762033</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortarolo M, Lo Coco D, Veglianese P, Vallarola A, Giordana MT, Marcon G, Beghi E, Poloni M, Strong MJ, Iyer AM, 2017. Amyotrophic lateral sclerosis, a multisystem pathology: insights into the role of TNF&#x3b1;. Mediators Inflamm. 2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610855</ArticleId><ArticleId IdType="pubmed">29081600</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, Ibarburu S, Barreto-N&#xfa;&#xf1;ez R, Varela V, Moura IC, Dubreuil P, Hermine O, Beckman JS, Barbeito L, 2017. Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI insight 2. 10.1172/jci.insight.95934</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.95934</ArticleId><ArticleId IdType="pmc">PMC5846907</ArticleId><ArticleId IdType="pubmed">29046475</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E, King PH, Si Y, Kwon Y, Varela V, Ibarburu S, Kovacs M, Moura IC, Beckman JS, Hermine O, 2018. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI insight 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6237484</ArticleId><ArticleId IdType="pubmed">30282815</ArticleId></ArticleIdList></Reference><Reference><Citation>Troost D, Van den Oord JJ, JONG JMBVDE, 1990. Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 16, 401&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pubmed">2263315</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Cagnin A, Turkheimer FE, Miller CCJ, Shaw CE, Brooks DJ, Leigh PN, Banati RB, 2004. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 15, 601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pubmed">15056468</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Sik A, Sakurai T, Nukina N, Takahashi R, Julien J-P, 2006. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. 9, 108&#x2013;118. 10.1038/nn1603</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1603</ArticleId><ArticleId IdType="pubmed">16369483</ArticleId></ArticleIdList></Reference><Reference><Citation>Vainchtein ID, Molofsky AV, 2020. Astrocytes and microglia: in sickness and in health. Trends Neurosci. 43, 144&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472912</ArticleId><ArticleId IdType="pubmed">32044129</ArticleId></ArticleIdList></Reference><Reference><Citation>Vallarola A, Sironi F, Tortarolo M, Gatto N, De Gioia R, Pasetto L, De Paola M, Mariani A, Ghosh S, Watson R, 2018. RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue. J. Neuroinflammation 15, 65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833072</ArticleId><ArticleId IdType="pubmed">29495962</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gurp E, Weimar W, Gaston R, Brennan D, Mendez R, Pirsch J, Swan S, Pescovitz MD, Ni G, Wang C, 2008. Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics. Am. J. Transplant. 8, 1711&#x2013;1718.</Citation><ArticleIdList><ArticleId IdType="pubmed">18557720</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D, Babu S, De Vocht J, Zurcher NR, Chew S, Tseng C-EJ, Loggia M, Koole M, Rezaei A, Schramm G, 2020a. Moving towards multicenter therapeutic trials in ALS: feasibility of data pooling using different TSPO positron emission tomography (PET) radioligands. J. Nucl. Med. jnumed-119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9364895</ArticleId><ArticleId IdType="pubmed">32169920</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D, Devrome M, Schramm G, De Vocht J, Deckers W, Baete K, Van Damme P, Koole M, Van Laere K, 2020b. Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics. Eur. J. Nucl. Med. Mol. Imaging 1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">32314027</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Weehaeghe D, Van Schoor E, De Vocht J, Koole M, Attili B, Celen S, Declercq L, Thal DR, Van Damme P, Bormans G, 2020c. TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study. J. Nucl. Med. 61, 604&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198372</ArticleId><ArticleId IdType="pubmed">31562223</ArticleId></ArticleIdList></Reference><Reference><Citation>Varghese AM, Sharma A, Mishra P, Vijayalakshmi K, Harsha HC, Sathyaprabha TN, Bharath SM, Nalini A, Alladi PA, Raju TR, 2013. Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis. Clin. Proteomics 10, 19. 10.1186/1559-0275-10-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1559-0275-10-19</ArticleId><ArticleId IdType="pmc">PMC4220794</ArticleId><ArticleId IdType="pubmed">24295388</ArticleId></ArticleIdList></Reference><Reference><Citation>Velebit J, Horvat A, Smoli&#x10d; T, Mihevc SP, Rogelj B, Zorec R, Vardjan N, 2020. Astrocytes with TDP-43 inclusions exhibit reduced noradrenergic cAMP and Ca 2+ signaling and dysregulated cell metabolism. Sci. Rep. 10, 1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7138839</ArticleId><ArticleId IdType="pubmed">32265469</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C, Amadio S, Cavaliere F, D&#x2019;Ambrosi N, Vacca F, Bernardi G, 2003. Extracellular ATP and neurodegeneration. Curr. Drug Targets. CNS Neurol. Disord. 2, 403&#x2013;412. 10.2174/1568007033482643</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1568007033482643</ArticleId><ArticleId IdType="pubmed">14683468</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallis N, Lau CL, Farg MA, Atkin JD, Beart PM, O&#x2019;Shea RD, 2018. SOD1 mutations causing familial amyotrophic lateral sclerosis induce toxicity in astrocytes: evidence for bystander effects in a continuum of astrogliosis. Neurochem. Res. 43, 166&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">28861673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang HA, Lee JD, Lee KM, Woodruff TM, Noakes PG, 2017. Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. Skelet. Muscle 7, 10. 10.1186/s13395-017-0128-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13395-017-0128-8</ArticleId><ArticleId IdType="pmc">PMC5455206</ArticleId><ArticleId IdType="pubmed">28571586</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe Hazuki, Atsuta N, Nakamura R, Hirakawa A, Watanabe Hirohisa, Ito M, Senda J, Katsuno M, Izumi Y, Morita M, Tomiyama H, Taniguchi A, Aiba I, Abe K, Mizoguchi K, Oda M, Kano O, Okamoto K, Kuwabara S, Hasegawa K, Imai T, Aoki M, Tsuji S, Nakano I, Kaji R, Sobue G, 2015. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Frontotemporal Degener. 16, 230&#x2013;236. 10.3109/21678421.2014.990036</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.990036</ArticleId><ArticleId IdType="pubmed">25548957</ArticleId></ArticleIdList></Reference><Reference><Citation>Weimer RM, Easley-Neal C, Foreman O, Sharma N, Zarrin AA, 2019. CSF1R ligands IL-34 and CSF1 are differentially required for microglia development and maintenance in white and gray matter brain regions. Front. Immunol. 10, 2199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6764286</ArticleId><ArticleId IdType="pubmed">31616414</ArticleId></ArticleIdList></Reference><Reference><Citation>Werry EL, Bright FM, Piguet O, Ittner LM, Halliday GM, Hodges JR, Kiernan MC, Loy CT, Kril JJ, Kassiou M, 2019. Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders. Int. J. Mol. Sci. 20, 3161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6650818</ArticleId><ArticleId IdType="pubmed">31261683</ArticleId></ArticleIdList></Reference><Reference><Citation>Wies Mancini VSB, Pasquini JM, Correale JD, Pasquini LA, 2019. Microglial modulation through colony-stimulating factor-1 receptor inhibition attenuates demyelination. Glia 67, 291&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">30456797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Pujol-Calder&#xf3;n F, Barro C, Stransky E, Blennow K, Michalak Z, Deuschle C, Jeromin A, Zetterberg H, Sch&#xfc;le R, H&#xf6;glund K, Kuhle J, Synofzik M, 2019. Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. Clin. Chem. Lab. Med. 57, 1556&#x2013;1564. 10.1515/cclm-2019-0015</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2019-0015</ArticleId><ArticleId IdType="pubmed">31251725</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosiski-Kuhn M, Caress JB, Cartwright MS, Hawkins GA, Milligan C, 2021. Interleukin 6 (IL6) level is a biomarker for functional disease progression within IL6R(358)Ala variant groups in amyotrophic lateral sclerosis patients. Amyotroph. Lateral Scler. Frontotemporal Degener. 22, 248&#x2013;259. 10.1080/21678421.2020.1813310</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1813310</ArticleId><ArticleId IdType="pubmed">32924606</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosiski-Kuhn M, Robinson M, Strupe J, Arounleut P, Martin M, Caress J, Cartwright M, Bowser R, Cudkowicz M, Langefeld C, Hawkins GA, Milligan C, 2019. IL6 receptor(358)Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis. Neurol. Neuroimmunol. neuroinflammation 6, e631. 10.1212/NXI.0000000000000631</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000631</ArticleId><ArticleId IdType="pmc">PMC6865852</ArticleId><ArticleId IdType="pubmed">31611269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S, Yi J, Zhang Y, Zhou J, Sun J, 2015. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol. Rep. 3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4425962</ArticleId><ArticleId IdType="pubmed">25847918</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Wu Y, Wang Y, Yang H, Du B, Di W, Xu X, Shi X, 2020. Cerebrospinal fluid MFG-E8 as a promising biomarker of amyotrophic lateral sclerosis. Neurol. Sci. Off. J. Ital. Neurol. Soc. Ital. Soc. Clin. Neurophysiol. 41, 2915&#x2013;2920. 10.1007/s10072-020-04416-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04416-3</ArticleId><ArticleId IdType="pubmed">32338335</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C-H, Davidson S, Harapas CR, Hilton JB, Mlodzianoski MJ, Laohamonthonkul P, Louis C, Low RRJ, Moecking J, De Nardo D, 2020. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell 183, 636&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanotti-Fregonara P, Pascual B, Rizzo G, Yu M, Pal N, Beers D, Carter R, Appel SH, Atassi N, Masdeu JC, 2018. Head-to-Head Comparison of 11C-PBR28 and 18F-GE180 for Quantification of the Translocator Protein in the Human Brain. J. Nucl. Med. 59, 1260&#x2013;1266.</Citation><ArticleIdList><ArticleId IdType="pubmed">29348317</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanotti-Fregonara P, Pascual B, Veronese M, Yu M, Beers D, Appel SH, Masdeu JC, 2019. Head-to-head comparison of 11 C-PBR28 and 11 C-ER176 for quantification of the translocator protein in the human brain. Eur. J. Nucl. Med. Mol. Imaging 46, 1822&#x2013;1829.</Citation><ArticleIdList><ArticleId IdType="pubmed">31152207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng Q, Shen J, Chen K, Zhou J, Liao Q, Lu K, Yuan J, Bi F, 2020. The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients. Sci. Rep. 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7398913</ArticleId><ArticleId IdType="pubmed">32747678</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai C-D, Zheng J-J, An B-C, Huang H-F, Tan Z-C, 2019. Intestinal microbiota composition in patients with amyotrophic lateral sclerosis: establishment of bacterial and archaeal communities analyses. Chin. Med. J. (Engl). 132, 1815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6759115</ArticleId><ArticleId IdType="pubmed">31306225</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, 2015. Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging. J. Neuroinflammation 12, 108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451729</ArticleId><ArticleId IdType="pubmed">26022249</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M, Zhou Q, Dorfman RG, Huang X, Fan T, Zhang H, Zhang J, Yu C, 2016. Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats. Bmc Gastroenterol. 16, 1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4967301</ArticleId><ArticleId IdType="pubmed">27473867</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang R, Gascon R, Miller RG, Gelinas DF, Mass J, Hadlock K, Jin X, Reis J, Narvaez A, McGrath MS, 2005. Evidence for systemic immune system alterations in sporadic amyotrophic lateral sclerosis (sALS). J. Neuroimmunol. 159, 215&#x2013;224. 10.1016/j.jneuroim.2004.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2004.10.009</ArticleId><ArticleId IdType="pubmed">15652422</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Wu S, Yi J, Xia Y, Jin D, Zhou J, Sun J, 2017. Target intestinal microbiota to alleviate disease progression in amyotrophic lateral sclerosis. Clin. Ther. 39, 322&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344195</ArticleId><ArticleId IdType="pubmed">28129947</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Appel SH, 2013. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 8, 888&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126425</ArticleId><ArticleId IdType="pubmed">23881705</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Henkel JS, Zhang W, Urushitani M, Julien J, Appel SH, 2010. Extracellular mutant SOD1 induces microglial-mediated motoneuron injury. Glia 58, 231&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2784168</ArticleId><ArticleId IdType="pubmed">19672969</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Beers DR, Hooten KG, Sieglaff DH, Zhang A, Kalyana-Sundaram S, Traini CM, Halsey WS, Hughes AM, Sathe GM, 2017. Characterization of gene expression phenotype in amyotrophic lateral sclerosis monocytes. JAMA Neurol. 74, 677&#x2013;685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5822209</ArticleId><ArticleId IdType="pubmed">28437540</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao W, Xie W, Le W, Beers DR, He Y, Henkel JS, Simpson EP, Yen AA, Xiao Q, Appel SH, 2004. Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. J. Neuropathol. Exp. Neurol. 63, 964&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">15453095</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O&#x2019;Banion MK, Stojanovic K, Sagare A, Boillee S, Cleveland DW, 2008. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat. Neurosci. 11, 420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895310</ArticleId><ArticleId IdType="pubmed">18344992</ArticleId></ArticleIdList></Reference><Reference><Citation>Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, Bellucci R, Raderschall E, Canning C, Soiffer RJ, 2006. IL-2 regulates FOXP3 expression in human CD4+ CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108, 1571&#x2013;1579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895505</ArticleId><ArticleId IdType="pubmed">16645171</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubiri I, Lombardi V, Bremang M, Mitra V, Nardo G, Adiutori R, Lu C-H, Leoni E, Yip P, Yildiz O, Ward M, Greensmith L, Bendotti C, Pike I, Malaspina A, 2018. Tissue-enhanced plasma proteomic analysis for disease stratification in amyotrophic lateral sclerosis. Mol. Neurodegener. 13, 60. 10.1186/s13024-018-0292-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0292-2</ArticleId><ArticleId IdType="pmc">PMC6223075</ArticleId><ArticleId IdType="pubmed">30404656</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfc;rcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, Akeju O, Catana C, Rosen BR, Cudkowicz ME, 2015. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [11C]-PBR28. NeuroImage Clin. 7, 409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>